

Refine Search

Search Results -

Term	Documents
FACTOR	913155
FACTORS	734419
VIII:C	455
VIII:CS	0
WILLEBRAND	4385
WILLEBRANDS	276
CONCENTRATE	287953
CONCENTRATES	86190
((FACTOR ADJ VIII:C) SAME (WILLEBRAND ADJ FACTOR) SAME CONCENTRATE).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	14
(FACTOR VIII:C SAME WILLEBRAND FACTOR SAME CONCENTRATE).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	14

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L16

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Tuesday, August 02, 2005 [Printable Copy](#) [Create Case](#)

Set
Name
 side by
 side

Query

Hit
Count

Set
Name
 result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ

L16 factor VIII:C same Willebrand factor same concentrate

14 L16

<u>L15</u>	process same producing same concentrate same (factor VIII:C) same (Willebrand factor)	2	<u>L15</u>
<u>L14</u>	process same producing same concentrate same factor VIIC same Willebrand factor	0	<u>L14</u>
<u>L13</u>	L2 and @py<2002	25	<u>L13</u>
<u>L12</u>	L10 and antibody	1	<u>L12</u>
<u>L11</u>	L10 and RCoF	0	<u>L11</u>
<u>L10</u>	L9 and producing	1	<u>L10</u>
<u>L9</u>	L8 and process	1	<u>L9</u>
<u>L8</u>	L7 and glycine	1	<u>L8</u>
<u>L7</u>	L5 and alkali metal	1	<u>L7</u>
<u>L6</u>	L4 and fractional precipitation	0	<u>L6</u>
<u>L5</u>	L4 and concentrate	3	<u>L5</u>
<u>L4</u>	L3 and L2 and L1	25	<u>L4</u>
<u>L3</u>	L2 and @py<2002	25	<u>L3</u>
<u>L2</u>	L1 and process same producing	60	<u>L2</u>
<u>L1</u>	factor VIIC same Willebrand	171	<u>L1</u>

END OF SEARCH HISTORY

side by side		<u>Count</u>	<u>Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
<u>L18</u>	(fractional precipitation) same (factor VIII:C) and (Willebrand factor)	3	<u>L18</u>
<u>L17</u>	(fractional precipitation) same (factor VIII:C) and (Willebrand factor) same metal	1	<u>L17</u>
<u>L16</u>	factor VIII:C same Willebrand factor same concentrate	14	<u>L16</u>
<u>L15</u>	process same producing same concentrate same (factor VIII:C) same (Willebrand factor)	2	<u>L15</u>
<u>L14</u>	process same producing same concentrate same factor VIIC same Willebrand factor	0	<u>L14</u>
<u>L13</u>	L2 and @py<2002	25	<u>L13</u>
<u>L12</u>	L10 and antibody	1	<u>L12</u>
<u>L11</u>	L10 and RCoF	0	<u>L11</u>
<u>L10</u>	L9 and producing	1	<u>L10</u>
<u>L9</u>	L8 and process	1	<u>L9</u>
<u>L8</u>	L7 and glycine	1	<u>L8</u>
<u>L7</u>	L5 and alkali metal	1	<u>L7</u>
<u>L6</u>	L4 and fractional precipitation	0	<u>L6</u>
<u>L5</u>	L4 and concentrate	3	<u>L5</u>
<u>L4</u>	L3 and L2 and L1	25	<u>L4</u>
<u>L3</u>	L2 and @py<2002	25	<u>L3</u>
<u>L2</u>	L1 and process same producing	60	<u>L2</u>
<u>L1</u>	factor VIIC same Willebrand	171	<u>L1</u>

END OF SEARCH HISTORY

STN

FILE 'RDISCLOSURE' ENTERED AT 11:05:21 ON 02 AUG 2005
COPYRIGHT (C) 2005 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 11:05:21 ON 02 AUG 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'SYNTHLINE' ENTERED AT 11:05:21 ON 02 AUG 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'TOXCENTER' ENTERED AT 11:05:21 ON 02 AUG 2005
COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 11:05:21 ON 02 AUG 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:05:21 ON 02 AUG 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 11:05:21 ON 02 AUG 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 11:05:21 ON 02 AUG 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 11:05:21 ON 02 AUG 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 11:05:21 ON 02 AUG 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 11:05:21 ON 02 AUG 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s factor VIII:C and Willebrand factor and concentrate and preparation

12 FILES SEARCHED...
21 FILES SEARCHED...
29 FILES SEARCHED...
32 FILES SEARCHED...
47 FILES SEARCHED...
59 FILES SEARCHED...
70 FILES SEARCHED...

L1 98 FACTOR VIII:C AND WILLEBRAND FACTOR AND CONCENTRATE AND PREPARAT
ION

=> s L1 and py<2002

1 FILES SEARCHED...
'2002' NOT A VALID FIELD CODE
4 FILES SEARCHED...
9 FILES SEARCHED...
12 FILES SEARCHED...
15 FILES SEARCHED...
16 FILES SEARCHED...
20 FILES SEARCHED...
'2002' NOT A VALID FIELD CODE
29 FILES SEARCHED...
'2002' NOT A VALID FIELD CODE
34 FILES SEARCHED...
'2002' NOT A VALID FIELD CODE
38 FILES SEARCHED...
44 FILES SEARCHED...
47 FILES SEARCHED...
52 FILES SEARCHED...
'2002' NOT A VALID FIELD CODE
'2002' NOT A VALID FIELD CODE
60 FILES SEARCHED...

62 FILES SEARCHED...
68 FILES SEARCHED...
70 FILES SEARCHED...
L2 77 L1 AND PY<2002

=> dup rem

ENTER L# LIST OR (END):L2

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, PS, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L2

L3 72 DUP REM L2 (5 DUPLICATES REMOVED)

=> d his

(FILE 'HOME' ENTERED AT 11:04:28 ON 02 AUG 2005)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, ...' ENTERED AT 11:05:21 ON 02 AUG 2005

L1 98 S FACTOR VIII:C AND WILLEBRAND FACTOR AND CONCENTRATE AND PREPA
L2 77 S L1 AND PY<2002
L3 72 DUP REM L2 (5 DUPLICATES REMOVED)

=> d L3 1-72 ibib,abs

L3 ANSWER 1 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2004:317310. USPATFULL

TITLE: Method for purifying factor VIII/vWF complex by cation-exchange chromatography

INVENTOR(S): Mitterer, Artur, Mannsdorf, AUSTRIA
Fischer, Bernhard, Vienna, AUSTRIA
Schonberger, Oyvind L., Vienna, AUSTRIA
Thomas-Urban, Kathrin, Freiburg, GERMANY, FEDERAL REPUBLIC OF
Dorner, Friedrich, Vienna, GERMANY, FEDERAL REPUBLIC OF
Eibl, Johann, Vienna, AUSTRIA
PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRALIA (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6831159	B1	20041214	
	WO 9838220		19980903	<--
APPLICATION INFO.:	US 2000-367459		20000508	(9)
	WO 1998-AT43		19980227	
			20000508	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1997-338	19970227
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Robinson, Hope A.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	656	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for recovering factor VIII/vWF-complex that involve binding factor VIII/vWF-complex from a protein solution to a cation exchanger and recovering factor VIII/vWF-complex by step-wise elution are disclosed. The recovered complex contains high-molecular vWF multimers.

Compositions containing factor VIII/vWF-complex as purified by cation exchange chromatography are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2003:161896 USPATFULL

TITLE: Method of recovering highly purified vWF or factor VIII/vWF-complex

INVENTOR(S): Mitterer, Artur, Mannsdorf, AUSTRIA
Fiedler, Christian, Vienna, AUSTRIA
Fischer, Bernhard, Vienna, AUSTRIA
Dorner, Friedrich, Vienna, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6579723	B1	20030617	
	WO 9838218		19980903	<--
APPLICATION INFO.:	US 1999-367362		19991021	(9)
	WO 1998-AT33		19980218	

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1997-339	19970227
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Le, Long V.	
ASSISTANT EXAMINER:	Gabel, Gailene R.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	51	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	1046	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for purifying factor VIII/vWF complex or free vWF by immunoaffinity chromatography in a form suitable for use as a medicament. Factor VIII/vWF complex or free vWF is recovered from an immunoaffinity adsorbent by using an eluting agent containing a zwitterionic species. The presence of the zwitterionic species allows for the use of mild conditions throughout the **preparation**, facilitating retention of molecular integrity, activity, and incorporation of the recovered proteins into pharmaceutical **preparations** without the need for additional stabilizers or preservatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2002:268871 USPATFULL

TITLE: Purification of von Willebrand factor by cation exchanger chromatography

INVENTOR(S): Fischer, Bernhard, Vienna, AUSTRIA
Schonberger, Oyvind L., Vienna, AUSTRIA
Mitterer, Artur, Mannsdorf, AUSTRIA
Fiedler, Christian, Vienna, AUSTRIA
Dorner, Friedrich, Vienna, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRALIA (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6465624	B1	20021015	
	WO 9838219		19980903	
APPLICATION INFO.:	US 1999-367460		19991021	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1997-337	19970227
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Robinson, Hope A.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	726	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are a method of recovering vWF in which vWF at a low salt concentration is bound to a cation exchanger and vWF having a high specific activity is recovered by fractionated elution, as well as a **preparation** having purified vWF obtainable by this method.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2002:160854 USPATFULL

TITLE: Method of chromatographically purifying or fractionating, respectively, von **Willebrand factor** from a VWF-containing starting materialINVENTOR(S): Siekmann, Juergen, Vienna, AUSTRIA
Turecek, Peter, Klosterneuburg, AUSTRIA
Schwarz, Hans-Peter, Vienna, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA
Fischer, Bernhard, Vienna, AUSTRIA
Mittéerer, Artur, Mannsdorf, AUSTRIA
Dorner, Friedrich, Vienna, AUSTRIA

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6414125	B1	20020702
	WO 9833820		19980806
APPLICATION INFO.:	US 1999-355865		19991021 (9)
	WO 1998-AT20		19980130
			19991021 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1997-176	19970204
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Robinson, Hope A.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	659	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a method of chromatographically purifying or fractionating, respectively, von **Willebrand factor** (vWF) from a vWF-containing starting material, comprising the following steps:

adsorbing the vWF from the starting material on avid collagen immobilized on a carrier,

separating the non-adsorbed portion and, optionally, washing the carrier,

eluting the vWF from immobilized collagen, and

recovering the purified vWF, as well as a pharmaceutical **preparation** comprising biologically active vWF which is bound to collagen in a stable manner.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2002:57411 USPATFULL

TITLE: Immunotolerant prothrombin complex **preparation**

INVENTOR(S): Schwarz, Hans-Peter, Vienna, AUSTRIA

Turecek, Peter, Klosterneuburg, AUSTRIA

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6358534	B1	20020319
	WO 9844942		19981015
APPLICATION INFO.:	US 2000-402582		20000128 (9)
	WO 1998-AT91		19980406
			20000128 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1997-594	19970408
	AT 1997-1592	19970919
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Witz, Jean C.	
LEGAL REPRESENTATIVE:	Oppenheimer Wolff & Donnelly LLP	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	928	

AB The invention relates to an immunotolerant prothrombin complex **preparation**, a method of producing this **preparation**, as well as the use of the **preparation** for producing a medicament,

L3 ANSWER 6 OF 72 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 1

ACCESSION NUMBER: 2001:524942 BIOSIS

DOCUMENT NUMBER: PREV200100524942

TITLE: Pasteurized, purified von Willebrand **factor concentrate** and a process for the **preparation** thereof.

AUTHOR(S): Heimbürger, Norbert [Inventor, Reprint author]; Kumpe, Gerhard [Inventor]; Wellner, Klaus [Inventor]

CORPORATE SOURCE: Marburg, Germany

ASSIGNEE: Aventis Behring GmbH, Marburg, Germany

PATENT INFORMATION: US 6239261 20010529

SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (May 29, 2001) Vol. 1246, No. 5. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

ENTRY DATE: Entered STN: 14 Nov 2001

Last Updated on STN: 23 Feb 2002

AB A process for the **preparation** of a **concentrate** of von Willebrand **factor** is described, entailing a solution of a complex of this factor with **factor VIII:C** being optionally pasteurized and treated with an anion exchanger, there being no binding of the von Willebrand **factor**.

L3 ANSWER 7 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2001:67424 USPATFULL

TITLE: Stable factor VIII/von Willebrand factor complex

INVENTOR(S): Fischer, Bernhard, Vienna, Austria
Mitterer, Artur, Mannsdorf, Austria
Dorner, Friedrich, Vienna, Austria
Eibl, Johann, Vienna, Austria

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6228613	B1	20010508	<--
	WO 9734930		19970925	
APPLICATION INFO.:	US 1998-142768		19981106	(9)
	WO 1997-AT55		19970313	
			19981106	PCT 371 date
			19981106	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-494	19960315
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Robinson, Hope A.	
LEGAL REPRESENTATIVE:	Heller Ehrman White & McAuliffe	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)	
LINE COUNT:	1098	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed a stable factor VIII/vWF-complex, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing this complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2001:63240 USPATFULL

TITLE: Pharmaceutical preparation for treating blood coagulation disorders

INVENTOR(S): Turecek, Peter, Klosterneuburg/Weidling, Austria
Schwarz, Hans-Peter, Vienna, Austria
Eibl, Johann, Vienna, Austria

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6224862	B1	20010501	<--
APPLICATION INFO.:	US 2000-521219		20000308	(9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-245339, filed on 5 Feb 1999 Division of Ser. No. US 1998-165745, filed on 6 Oct 1998, now patented, Pat. No. US 6039945 Division of Ser. No. US 1997-821763, filed on 20 Mar 1997, now patented, Pat. No. US 5866122, issued on 2 Feb 1999			

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-518	19960320
	AT 1996-1573	19960904
	AT 1996-1673	19960920
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Weddington, Kevin E.	

LEGAL REPRESENTATIVE: Heller Ehrman White & McAuliffe
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1454

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a pharmaceutical **preparation** for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2001:48216 USPATFULL

TITLE: Process for preparing factor V-deficient plasma, and a deficient plasma which is obtained in this way
INVENTOR(S): Kraus, Michael, Marburg, Germany, Federal Republic of
Aillaud, Erika, Rauschenberg, Germany, Federal Republic of
Drescher, Heinz-Hermann, Neustadt, Germany, Federal Republic of
PATENT ASSIGNEE(S): Dade Behring Marburg GmbH, Marburg, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6211344	B1	20010403	<--
APPLICATION INFO.:	US 1997-915585		19970821 (8)	

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19634312	19960824
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Saunders, David	
ASSISTANT EXAMINER:	De Cloux, Amy	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	457	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a process for preparing factor V-deficient plasma, in particular a factor V-deficient plasma from a starting plasma using antibodies, and a deficient plasma which is obtained in this way.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2001:26019 USPATFULL

TITLE: Recombinant factor VIII binding peptides
INVENTOR(S): Chen, Li Ang, Waverly, TN, United States
Buettner, Joseph A., Raleigh, NC, United States
Carbonell, Ruben G., Raleigh, NC, United States
PATENT ASSIGNEE(S): Bayer Corporation, Berkeley, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6191256	B1	20010220	<--
APPLICATION INFO.:	US 1998-196934		19981120 (9)	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Low, Christopher S. F.			
ASSISTANT EXAMINER:	Mohamed, Abdel A.			
LEGAL REPRESENTATIVE:	Beck, Michael J., Giblin, James A.			
NUMBER OF CLAIMS:	3			
EXEMPLARY CLAIM:	1			

LINE COUNT: 627

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Peptides that have domains that bind to recombinant factor VIII (rFVIII) are disclosed. A method of rFVIII binding assay using the peptides deduced from a combinatorial library in a filtration plate process is described. A method of using peptides having these available binding domains in an affinity chromatography process to purify factor VIII is also taught.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2000:174602 USPATFULL

TITLE: ~~Pharmaceutical~~ **preparation** for treating blood coagulation disorders

INVENTOR(S): Turecek, Peter, Klosterneuburg/Weidling, Austria
Schwarz, Hans-Peter, Vienna, Austria
Eibl, Johann, Vienna, Austria

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6165974		20001226 <--
APPLICATION INFO.:	US 1999-245339		19990205 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-165745, filed on 6 Oct 1998, now patented, Pat. No. US 6039945 which is a division of Ser. No. US 1997-821763, filed on 20 Mar 1997, now patented, Pat. No. US 5866122, issued on 2 Feb 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-518	19960320
	AT 1996-1573	19960904
	AT 1996-1673	19960920

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1552

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a pharmaceutical **preparation** for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2000:105877 USPATFULL

TITLE: ~~Method~~ **for isolation of highly pure von willebrand factor**

INVENTOR(S): Fischer, Bernhard, Vienna, Austria
Mitterer, Artur, Orth/Donau, Austria
Dorner, Friedrich, Vienna, Austria
Schwarz, Hans-Peter, Vienna, Austria
Turecek, Peter, Vienna, Austria
Eibl, Johann, Vienna, Austria
Falkner, Falko-Guenter, Orth/Donau, Austria
Schlokat, Uwe, Orth/Donau, Austria
Mundt, Wolfgang, Vienna, Austria
Reiter, Manfred, Vienna, Austria
Den-Bouwmeester, Renate, Vienna, Austria

PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Vienna, Austria (non-U.S.)

corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6103693		20000815	<--
APPLICATION INFO.:	US 1997-898130		19970722	(8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-653298, filed on 24 May 1996, now patented, Pat. No. US 5854403 which is a continuation of Ser. No. WO 1995-EP3892, filed on 2 Oct 1995			

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1994-4435485	19941004
	WO 1995-EP3892	19951002
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Patterson, Jr., Charles L.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	793	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method for isolation of highly pure von **Willebrand Factor** in which recombinant von **Willebrand Factor** (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt.

The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active.

Further, the invention relates to a pharmaceutical **preparation** that contains rvWF, which is comprised of multimers with a high structural integrity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2000:101870 USPATFULL

TITLE: Pharmaceutical **preparation** for treating blood coagulation disorders

INVENTOR(S): Turecek, Peter, Klosterneuburg/Weidling, Austria
Schwarz, Hans-Peter, Vienna, Austria
Eibl, Johann, Vienna, Austria

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6099837		20000808	<--
APPLICATION INFO.:	US 1999-244762		19990205	(9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-165745, filed on 6 Oct 1998 which is a division of Ser. No. US 1997-821763, filed on 20 Mar 1997, now patented, Pat. No. US 5866122			

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-518	19960320
	AT 1996-1573	19960904
	AT 1996-1673	19960920
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Weddington, Kevin E.	

LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1533

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a pharmaceutical **preparation** for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 72 USPATFULL on STN

ACCESSION NUMBER: 2000:34192 USPATFULL

TITLE: Pharmaceutical **preparation** for treating blood coagulation disorders

INVENTOR(S): Turecek, Peter, Klosterneuburg/Weidling, Austria
Schwarz, Hans-Peter, Vienna, Austria
Eibl, Johann, Vienna, Austria

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6039945		20000321	<--
APPLICATION INFO.:	US 1998-165745		19981006 (9)	
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-821763, filed on 20 Mar 1997, now patented, Pat. No. US 5866122			

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-518	19960320
	AT 1996-1573	19960904
	AT 1996-1673	19960920

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1524

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a pharmaceutical **preparation** for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 72 USPATFULL on STN

ACCESSION NUMBER: 1999:75764 USPATFULL

TITLE: Protein formulation comprising coagulation factor VIII or factor IX in an aqueous solution

INVENTOR(S): Osterberg, Thomas, Stockholm, Sweden
Fatouros, Angelica, Stockholm, Sweden

PATENT ASSIGNEE(S): Pharmacia & Upjohn AB, Stockholm, Sweden (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5919908		19990706	<--
	WO 9630041		19961003	<--
APPLICATION INFO.:	US 1997-913263		19971126 (8)	
	WO 1996-SE419		19960309	
			19971126	PCT 371 date
			19971126	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1995-1189	19950331
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Tsang, Cecilia J.	
ASSISTANT EXAMINER:	Mohamed, Abdel A.	
LEGAL REPRESENTATIVE:	Dinsmore & Shohl LLP	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
LINE COUNT:	791	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A final drug product comprises a plasma protein selected from the group consisting of coagulation factor VIII and factor IX, in an aqueous solution. The concentration of oxygen in the solution is reduced and/or the solution contains an antioxidant. The solution further contains a carbohydrate in a concentration of at least 350 mg/ml. The protein activity after storage for at least 6 months at a temperature of from 0° C. to 40° C. is from 70% to 130% of its initial value.

In a process for preparing the final drug product and a method for improving the long-term stability of coagulation factor VIII or factor IX in an aqueous solution, a carbohydrate is included in the solution in a concentration of at least 350 mg/ml and the solution is stored in its final container under an oxygen-reduced atmosphere or includes an antioxidant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 72 USPATFULL on STN

ACCESSION NUMBER: 1999:75622 USPATFULL

TITLE: Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer

INVENTOR(S): Osterberg, Thomas, Stockholm, Sweden
Fatouros, Angelica, Stockholm, Sweden

PATENT ASSIGNEE(S): Pharmacia & Upjohn Aktiebolag, Stockholm, Sweden
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5919766		19990706 <--
APPLICATION INFO.:	US 1997-863198		19970527 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-244266, filed on 20 May 1994, now patented, Pat. No. US 5733873		

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1992-2878	19921002
	SE 1993-1580	19930507
	SE 1993-2006	19930611
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Degen, Nancy	
LEGAL REPRESENTATIVE:	Pollock, Vande Sande & Amernick	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	618	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel composition comprising coagulation Factor VIII and a non-ionic surfactant such as block co-polymers, e.g. polyoxamers or polyoxyethylene (20) fatty acid esters e.g. polysorbate 20 or polysorbate 80 as a stabilizer. The composition can also comprise sodium chloride, calcium chloride, L-histidine and/or sugars or sugar alcohols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 72 USPATFULL on STN

ACCESSION NUMBER: 1999:30944 USPATFULL

TITLE: Method for isolation of highly pure von
willebrand factor

INVENTOR(S): Fischer, Bernhard, Vienna, Austria
Mitterer, Artur, Orth/Donau, Austria
Dorner, Friedrich, Vienna, Austria
Schwarz, Hans-Peter, Vienna, Austria
Turecek, Peter, Vienna, Austria
Eibl, Johann, Vienna, Austria
Falkner, Falko-Guenter, Orth/Donau, Austria
Schlokat, Uwe, Orth/Donau, Austria
Mundt, Wolfgang, Vienna, Austria
Reiter, Manfred, Vienna, Austria
Den-Bouwmeester, Renate, Vienna, Austria
PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Vienna, Austria (non-U.S.
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5880265		19990309	<--
APPLICATION INFO.:	US 1997-898129		19970722	(8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-653298, filed on 24 May 1996			

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1994-4435485	19941004
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Patterson, Jr., Charles L.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	787	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method for isolation of highly pure von
Willebrand Factor in which recombinant von
Willebrand Factor (rvWF) is chromatographically
purified by anion exchange chromatography on an anion exchanger of the
quaternary amino type in a buffer solution comprising buffer substances
and optionally salt.

The buffer solutions are preferably free of stabilizers, amino acids and
other additives. According to this method, highly pure recombinant vWF
can be obtained, which is free from blood plasma proteins, especially
free from Factor VIII, and is physiologically active.

Further, the invention relates to a pharmaceutical **preparation**
that contains rvWF, which is comprised of multimers with a high
structural integrity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 72 USPATFULL on STN

ACCESSION NUMBER: 1999:27611 USPATFULL

TITLE: Method for isolation of highly pure von
Willebrand Factor

INVENTOR(S): Fischer, Bernhard, Vienna, Austria
Mitterer, Artur, Orth/Donau, Austria
Dorner, Friedrich, Vienna, Austria
Schwarz, Hans-Peter, Vienna, Austria
Turecek, Peter, Vienna, Austria
Eibl, Johann, Vienna, Austria
Falkner, Falko-Guenter, Orth/Donau, Austria
Schlokat, Uwe, Orth/Donau, Austria

Mundt, Wolfgang, Vienna, Austria
 Reiter, Manfred, Vienna, Austria
 Den-Bouwmeester, Renate, Vienna, Austria
 PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Vienna, Austria (non-U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5877152		19990302 <--
APPLICATION INFO.:	US 1997-898131		19970722 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-653298, filed on 24 May 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1994-4435485	19941004
	WO 1995-EP3892	19951002
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Patterson, Jr., Charles L.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	767	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method for isolation of highly pure von **Willebrand Factor** in which recombinant von **Willebrand Factor** (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt.

The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active.

Further, the invention relates to a pharmaceutical **preparation** that contains rvWF, which is comprised of multimers with a high structural integrity

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 72 USPATFULL on STN
 ACCESSION NUMBER: 1999:15483 USPATFULL
 TITLE: **Pharmaceutical preparation** for treating blood coagulation disorders
 INVENTOR(S): Turecek, Peter, Weidling, Austria
 Schwarz, Hans-Peter, Vienna, Austria
 Eibl, Johann, Vienna, Austria
 PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5866122		19990202 <--
APPLICATION INFO.:	US 1997-821763		19970320 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-518	19960320
	AT 1996-1573	19960904
	AT 1996-1673	19960920
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Weddington, Kevin E.	
LEGAL REPRESENTATIVE:	Foley & Lardner	

NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1609

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a pharmaceutical **preparation** for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 20 OF 72 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 1999:239963 SCISEARCH

THE GENUINE ARTICLE: 176UU

TITLE: Preclinical evaluation of recombinant von **Willebrand factor** in a canine model of von Willebrand disease

AUTHOR: Schwarz H P (Reprint); Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek P L

CORPORATE SOURCE: Baxter Hyland Immuno, Ind Str 67, A-1220 Vienna, Austria (Reprint); Baxter Hyland Immuno, A-1220 Vienna, Austria

COUNTRY OF AUTHOR: Austria

SOURCE: WIENER KLINISCHE WOCHENSCHRIFT, (12 MAR 1999)

Vol. 111, No. 5, pp. 181-191.

ISSN: 0043-5325.

PUBLISHER: SPRINGER-VERLAG WIEN, SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 41

ENTRY DATE: Entered STN: 1999

Last Updated on STN: 1999

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Dutch Kooiker dogs with hereditary von Willebrand disease (vWD) have undetectable levels of von **Willebrand factor** (vWF), resulting in spontaneous hemorrhage of mucosal surfaces similar to the clinical picture of vWD in humans. We used this canine model of vWD to study the in vivo effects of a new recombinant von **Willebrand factor** (rvWF) **preparation** that contained all species of vWF multimers compared with an rvWF fraction containing only low molecular weight multimers (LMW-rvWF) and with a plasma-derived factor VIII/vWF **concentrate** (pdvWF). Administration of rvWF in these vWF-deficient dogs resulted in a vWF:Ag half-life of 21.6 hours in one dog and 22.1 hours in a second dog. Administration of pdvWF resulted in a half-life for vWF:Ag of 7.7 hours, and LMW-rvWF, 9 hours. The in vivo recovery of vWF:Ag after administration of rvWF was 59, 64 and 70% in three dogs, respectively; 33% after pdvWF, and 92% after LMW-rvWF. The in vivo recovery of ristocetin cofactor (RCoF) was 78, 110 and 120% for rvWF, and 25% for pdvWF. Both rvWF and pdvWF caused increases in factor VIII. Although no effect was seen on bleeding time at the dosages used, the rate of blood flow from cuticle wounds was reduced after a single bolus administration of rvWF. The rvWF was able to control a severe nose bleed in one dog.

L3 ANSWER 21 OF 72 USPATFULL on STN

ACCESSION NUMBER: 1998:162660 USPATFULL

TITLE: ~~Method~~ for isolation of highly pure von **Willebrand Factor**

INVENTOR(S): Fischer, Bernhard, Vienna, Austria
Mitterer, Artur, Orth/Donau, Austria
Dorner, Friedrich, Vienna, Austria
Schwarz, Hans-Peter, Vienna, Austria
Turecek, Peter, Vienna, Austria
Eibl, Johann, Vienna, Austria
Falkner, Falko-Guenter, Orth/Donau, Austria
Schlokat, Uwe, Orth/Donau, Austria

Mundt, Wolfgang, Vienna, Austria
Reiter, Manfred, Vienna, Austria
Den-Bouwmeester, Renate, Vienna, Austria
Immuno Aktiengesellschaft, Vienna, Austria (non-U.S.
corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5854403		19981229	<--
APPLICATION INFO.:	US 1996-653298		19960524	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1994-4435485	19941004
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Patterson, Jr., Charles L.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	813	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method for isolation of highly pure von
Willebrand Factor in which recombinant von
Willebrand Factor (rvWF) is chromatographically
purified by anion exchange chromatography on an anion exchanger of the
quaternary amino type in a buffer solution comprising buffer substances
and optionally salt. The buffer solutions are preferably free of
stabilizers, amino acids and other additives. According to this method,
highly pure recombinant rvWF can be obtained, which is free from blood
plasma proteins, especially free from Factor VIII, and is
physiologically active. Further, the invention relates to a
pharmaceutical **preparation** that contains rvWF, which comprises
multimers with a high structural integrity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 22 OF 72 USPATFULL on STN

ACCESSION NUMBER: 1998:159734 USPATFULL
TITLE: Process for producing a protein
INVENTOR(S): Adamson, Lars, Lidingo, Sweden
Walum, Erik, Akersberga, Sweden
Dixelius, Johan, Uppsala, Sweden
Lie, Kristina Lima, Stockholm, Sweden
PATENT ASSIGNEE(S): Pharmacia & Upjohn AB, Stockholm, Sweden (non-U.S.
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5851800		19981222	<--
APPLICATION INFO.:	US 1997-852783		19970507	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1996-1855	19960514
	US 1996-18874P	19960529 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Weber, Jon P.	
LEGAL REPRESENTATIVE:	Dinsmore & Shohl LLP	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	719	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process is presented for reducing the detrimental influence of certain
proteases on recombinant human protein and polypeptide production in a
cell culture, which comprises adding an inhibitor of metal-dependent

proteases or chymotrypsins to the cell culture medium. The cell culture medium for cultivating cells expressing and secreting a biologically active recombinant human polypeptide contains an inhibitor of metal-dependent proteases or chymotrypsins, or a combination thereof. Recombinant factor VIII which has been produced in a cell culture medium according to the present process is useful for the manufacture of a medicament for administration to a patient having the symptoms of hemophilia A and for treatment of hemophilia A by administration of a therapeutically effective amount of recombinant factor VIII.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 23 OF 72 USPATFULL on STN

ACCESSION NUMBER: 1998:107999 USPATFULL

TITLE: Antiplasma animal model

INVENTOR(S): Eibl, Johann, Vienna, Austria

Turecek, Peter, Klosterneuburg Weidling, Austria

Schwarz, Hans Peter, Vienna, Austria

PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5804159		19980908	<--
APPLICATION INFO.:	US 1996-663031		19960607	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1995-987	19950609
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chambers, Jasmine C.	
ASSISTANT EXAMINER:	Hauda, Karen M.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	737	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed an anti-plasma antibody **preparation** for treatment of a mammal, which **preparation** is capable of directly or indirectly inhibiting and/or eliminating several blood factors, a method of producing such a **preparation** and a method of evaluating substances for treating clotting disorders by using said anti-plasma antibody **preparation**. There is further disclosed a method of determining the bleeding characteristics of a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 24 OF 72 USPATFULL on STN

ACCESSION NUMBER: 1998:33896 USPATFULL

TITLE: Composition comprising coagulation factor VIII formulation, process for its **preparation** and use of a surfactant as stabilizer

INVENTOR(S): Osterberg, Thomas, Stockholm, Sweden

Fatouros, Angelica, Stockholm, Sweden

PATENT ASSIGNEE(S): Pharmacia & Upjohn AB, Stockholm, Sweden (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5733873		19980331	<--
	WO 9407510		19940414	
APPLICATION INFO.:	US 1994-244266		19940520	(8)
	WO 1993-SE793		19931001	
			19940520	PCT 371 date
			19940520	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1992-2878	19921002
	SE 1993-1580	19930507
	SE 1993-2006	19930611
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Degen, Nancy	
LEGAL REPRESENTATIVE:	Pollock, Vande Sande & Priddy	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	650	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition comprising coagulation factor VIII and a non-ionic surfactant such as block copolymers, e.g., polyoxamers or polyoxyethylene (20) sorbitan fatty acid esters, e.g., polysorbate 20 or polysorbate 80 as stabilizer is provided. The composition can also comprise sodium chloride, calcium chloride, L-histidine and/or sugars or sugar alcohols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 25 OF 72 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 1999:59508 SCISEARCH

THE GENUINE ARTICLE: ~~156NX~~

TITLE: Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease

AUTHOR: Schwarz H P (Reprint); Dorner F; Mitterer A; Mundt W; Schlokot U; Pichler L; Turecek P L

CORPORATE SOURCE: Immuno AG Wien, Industriest. 67, A-1220 Vienna, Austria (Reprint); Baxter Healthcare Corp, Hyland Immuno Div, Vienna, Austria

COUNTRY OF AUTHOR: Austria

SOURCE: HAEMOPHILIA, (1998) Vol. 4, Supp. [3], pp. 53-62

PUBLISHER: ISSN: 1351-8216. BLACKWELL SCIENCE LTD, P O BOX 88, OSNEY MEAD, OXFORD OX2 ONE, OXON, ENGLAND.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 35

ENTRY DATE: Entered STN: 1999

Last Updated on STN: 1999

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Dutch Kooiker dogs with hereditary von Willebrand disease have undetectable levels of von Willebrand factor (vWF), resulting in spontaneous haemorrhage of mucosal surfaces similar to the clinical picture of von Willebrand disease in humans. We used this canine model of von Willebrand disease to study the in vivo effects of a new recombinant von Willebrand factor (rvWF) preparation that contained all species of vWF multimers compared with a rvWF fraction containing only low molecular weight multimers (LMW-rvWF) and with a plasma-derived factor.VIII/vWF concentrate (pdvWF). Administration of rvWF in these vWF-deficient dogs resulted in a vWF:Ag half-life of 21.6 h in one dog and 22.1 h in a second dog. Administration of pdvWF resulted in a half-life for vWF:Ag of 7.7 h, and LMW-rvWF, 9 h. The in vivo recovery of vWF:Ag after administration of rvWF was 59%, 64% and 70% in three dogs, respectively; 33% after pdvWF, and 92% after LMW-rvWF. The in vivo recovery of ristocetin cofactor (RCoF) was 78%, 110% and 120% for rvWF, and 25% for pdvWF. Both rvWF and pdvWF caused increases in FVIII. Although no effect was seen on bleeding time at the dosages used, the rate of blood flow from cuticle wounds was reduced after a single bolus administration of rvWF. The rvWF was able to control a severe nose bleed in one dog.

L3 ANSWER 26 OF 72 IFIPAT COPYRIGHT 2005 IFI on STN

AN 02807564 IFIPAT;IFIUDB;IFICDB
 TITLE: FACTOR VIII BINDING DOMAIN OF VON WILLEBRAND
 FACTOR
 INVENTOR(S): Foster, Paul A, San Diego, CA
 Fulcher, Carol A, La Jolla, CA
 Zimmerman, Theodore S, La Jolla, CA
 PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA
 PRIMARY EXAMINER: Jacobson, Dian C

	NUMBER	PK	DATE
PATENT INFORMATION:	US 5597711	A	19970128
	(CITED IN 001 LATER PATENTS)		
APPLICATION INFORMATION:	US 1995-410574		19950324
EXPIRATION DATE:	28 Jan 2014		

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
CONTINUATION OF:	US 1987-45032	19870501	5043429
CONTINUATION OF:	US 1993-125559	19930923	ABANDONED
DIVISION OF:	US 1991-725560	19910703	5260274
FAMILY INFORMATION:	US 5597711	19970128	
	US 5043429		
	US 5260274		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	CHEMICAL		
	GRANTED		

NUMBER OF CLAIMS: 6
 AB Peptides which inhibit the binding of von Willebrand
 Factor to Factor VIII. Monoclonal antibodies capable of
 specifically binding to the region of von Willebrand
 Factor containing the Factor VIII binding domain. Improved
 methods of preparing Factor VIII.

CLMN 6

L3 ANSWER 27 OF 72 USPATFULL on STN
 ACCESSION NUMBER: 97:99199 USPATFULL
 TITLE: Retroviral delivery of full length factor VIII
 INVENTOR(S): Bodner, Mordechai, San Diego, CA, United States
 De Polo, Nicholas J., Solana Beach, CA, United States
 Chang, Stephen, Poway, CA, United States
 Hsu, David Chi-Tang, San Diego, CA, United States
 Respass, James G., San Diego, CA, United States
 PATENT ASSIGNEE(S): Chiron Viagene, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5681746		19971028	<--
APPLICATION INFO.:	US 1994-366851		19941230	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Crouch, Deborah			
ASSISTANT EXAMINER:	Schmuck, Jill			
LEGAL REPRESENTATIVE:	Kruse, Norman J., Blackburn, Robert P.			
NUMBER OF CLAIMS:	14			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)			
LINE COUNT:	3229			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Retroviral vectors for directing expression of full length factor VIII
 in transduced host cells, plasmids encoding the same, and host cells
 transformed, transfected, or transduced therewith are disclosed. Also
 disclosed are retroviral particles comprising such retrovital vectors,
 as are methods for making such particles in suitable packaging cells.
 Retroviral particles so produced may be amphotropic, ecotropic,
 polytropic, or xenotropic; alternatively, they may comprise chimeric or

hybrid envelope proteins to alter host range. Also described are retroviral particles comprising retroviral vectors for directing full length factor VIII expression which are complement resistant. Pharmaceutical compositions comprising retroviral particles of the invention are also disclosed, as are methods of treating mammals, particularly humans, afflicted with hemophilia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 28 OF 72 USPATFULL on STN

ACCESSION NUMBER: ~~97~~:75993 USPATFULL

TITLE: Recombinant human factor VIII derivatives

INVENTOR(S): Almstedt, Annelie B., Stockholm, Sweden
Gray (Hellstrom), Eva Maria, Stockholm, Sweden
Lind, Peter, Upsala, Sweden
Ljung, Catherine, Vallingby, Sweden
Sandberg, Helena Inga, Bromma, Sweden
Spira, Jack, Solna, Sweden
Sydow-Backman, Mona, Saltsjobaden, Sweden
Wiman, Helena, Stockholm, Sweden

PATENT ASSIGNEE(S): Kabi Pharmacia AB, Upsala, Sweden (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5661008		19970826
APPLICATION INFO.:	US 1995-462917		19950605 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-934495, filed on 17 Dec 1992, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1991-799	19910315
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Jacobson, Dian C.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	833	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A DNA sequence coding for a biologically active recombinant human factor VIII derivative, comprising a first DNA segment coding for the amino acids 1 through 740 of human factor VIII and a second DNA segment coding for the amino acids 1649 through 2332 of human factor VIII, said segments being interconnected by a linker DNA segment coding for a linker peptide of at least 3 amino acid residues and up to about 10 amino acid residues which are selected from lysine and arginine; recombinant expression vector comprising such DNA sequence; host cells of animal origin transformed with such recombinant expression vector; a process for the manufacture of recombinant human factor VIII derivative; and human factor VIII derivative containing the heavy chain and the light chain linked by metal ion bond.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 29 OF 72 USPATFULL on STN

ACCESSION NUMBER: 97:73722 USPATFULL

TITLE: Anion exchange process for the purification of Factor VIII

INVENTOR(S): Bhattacharya, Prabir, Walnut, CA, United States
Motokubota, Toshiharu, Arcadia, CA, United States
Fedalizo, Norman M., Rowland Heights, CA, United States
PATENT ASSIGNEE(S): Alpha Therapeutic Corporation, Los Angeles, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5659017 19970819 <--
APPLICATION INFO.: US 1995-554724 19951107 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
LEGAL REPRESENTATIVE: Christie, Parker & Hale, LLP
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 866

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A new method for purifying Factor VIII complex from an impure protein fraction, usually cryoprecipitate, is disclosed. The cryoprecipitate is dissolved in a heparin solution. Then Factor VIII complex is initially purified by polyethylene glycol precipitation. The Factor VIII containing supernatant collected after the precipitation is loaded into an anion exchange column that has a quaternary amino ethyl group. The Factor VIII complex is then eluted from the column with a buffer comprising from about 0.14M to about 0.20M CaCl₂. The final step in the purification is to precipitate the Factor VIII complex in the presence of glycine and sodium chloride. The precipitated Factor VIII complex is then reconstituted and stabilized. The reconstituted Factor VIII complex can then be lyophilized and dry heated to obtain a final Factor VIII product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 30 OF 72 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 1997-35135 DRUGU T

TITLE: Successful cardiac surgery in a young girl with type 2a von Willebrand disease using continuous infusion of Hemate-P.

AUTHOR: Naqvi A; Endres Brooks J; Montgomery R R; Stain A M; Sparling C; Klaassen R; Blanchette V S

LOCATION: Toronto, Ont., Can.; Milwaukee, Wis., USA

SOURCE: Thromb.Haemostasis (Suppl., 514, 1997) 1 Ref.

CODEN: THHADQ ISSN: 0340-6245

AVAIL. OF DOC.: Division of Hematology, the Hospital for Sick Children, Toronto, Ontario, Canada.

LANGUAGE: English

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

FILE SEGMENT: Literature

AN 1997-35135 DRUGU T

AB Here the Authors report the successful use of continuous infusion therapy using a factor VIII/von Willebrand factor

concentrate (Hemate-P) to provide hemostatic cover in a 6-yr-old girl with type 2A von Willebrand disease (vWd) admitted for elective closure of a perimembranous ventriculoseptal defect using temporary cardiopulmonary bypass and moderate hypothermia. The patient also received desmopressin (DDAVP) during the preoperative period. The patient experienced no untoward bleeding in the operative or post-operative periods and no infectious complications were noted. (conference abstract).

ABEX Baseline coagulation results were as follows: platelet count 345 x 10⁹/l, bleeding time 17 min (normal less than 7 min), FVIII:C 1.47 U/ml; vWf:Ag 0.84 U/ml, and vWf R:Co 0.42 U/ml. Preoperatively the patient received 74 U/kg of Hemate-P and 0.3 ug/kg of DDAVP by i.v. infusion with correction of the bleeding time and haemostatic parameters (post infusion bleeding time 6 min; FVIII:C 4.63 U/ml; vWf:Ag 2.25 U/ml; and vWf R:Co 2.06 U/ml). Postoperatively the patient was maintained on a continuous infusion of Hemate-P for 7 days (initial rate 2.7 U/kg/hr, concentration 25 U/ml, decreasing to 0.4 U/kg/hr, concentration 12.5 U/ml). Hemate-P was reconstituted as per manufacturers instruction, dispensed in a 60 ml syringe and administered through a high-precision infusion pump. The one exception was the last **concentrate preparation**; this material was diluted 1:1 with normal saline (final concentration 6.5 U/ml). Coagulation testing on samples of

reconstituted Hemate-P (multiple lots) demonstrated near normal distribution of vWf multimers for up to 40 hr post reconstitution. Following infusion of the Hemate-P, the patient's vWf multimeric pattern nearly normalized with reconstitution of the high molecular weight multimeric forms. Sustained levels of both von-Willebrand factor and factor VIII:C were kept at hemostatic levels or above through the continuous infusion of Hemate-P in this patient with type 2A von Willebrand disease. The ratio of vWf R:Co and vWf:Ag were similar during the treatment period. (PH)

L3 ANSWER 31 OF 72 USPATFULL on STN

ACCESSION NUMBER: 96:94557 USPATFULL
 TITLE: Stabilized factor VIII preparations
 INVENTOR(S): Freudenberg, Wilfried, C olbe-Sch onstadt, Germany, Federal Republic of
 PATENT ASSIGNEE(S): Behringwerke Aktiengesellschaft, Marburg, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5565427		19961015 <--
APPLICATION INFO.:	US 1994-235241		19940429 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-82911, filed on 29 Jun 1993, now abandoned which is a continuation of Ser. No. US 1992-864610, filed on 7 Apr 1992, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1991-4111393	19910409
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Weimar, Elizabeth C.	
ASSISTANT EXAMINER:	Touzeau, P. Lynn	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	238	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention relates to stabilized solutions with F VIII coagulation activity, to a process for the preparation thereof and to the use thereof.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 32 OF 72 USPATFULL on STN

ACCESSION NUMBER: 96:5889 USPATFULL
 TITLE: Antihemophilic factor stabilization
 INVENTOR(S): Johnson, Alan J., 127 W. 12th St., New York, NY, United States 10011
 Fulton, Anne J., 515 Avon Dr., East Windsor, NJ, United States 08520

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5484890		19960116 <--
APPLICATION INFO.:	US 1993-138481		19931015 (8)
DISCLAIMER DATE:	20110111		
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-790390, filed on 12 Nov 1991, now patented, Pat. No. US 5278289		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Russel, Jeffrey E.		
LEGAL REPRESENTATIVE:	Darby & Darby		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	927		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB A method of recovering a purified and stabilized protein having antihemophilic factor activity (Factor VIII), from a biological sample containing Factor VIII, at least one destabilizing protease impurity, i.e. thrombin, and optionally one or more propotease impurity, is provided. The biological sample is contacted with a protease removing and/or inhibiting agent, thereby inhibiting and/or removing the destabilizing protease impurity. The method provides increased yield and resolution of Factor VIII. Also provided are purified and stabilized Factor VIII non-lyophilized, liquid in compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 33 OF 72 USPATFULL on STN

ACCESSION NUMBER: 95:105944 USPATFULL
TITLE: Ultrapurification process for factor VIII
INVENTOR(S): Neslund, Gerard G., Diamond Bar, CA, United States
Liu, Shu-Len, Cerritos, CA, United States
Griffith, Michael J., Claremont, CA, United States
PATENT ASSIGNEE(S): Baxter International Inc., Deerfield, IL, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5470954		19951128 <--
APPLICATION INFO.:	US 1993-140695		19931021 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-887387, filed on 21 May 1992, now abandoned which is a continuation of Ser. No. US 1988-167902, filed on 28 Mar 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-32800, filed on 31 Mar 1987, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Sayala, Chhaya D.		
LEGAL REPRESENTATIVE:	Condino, Debra D.		
NUMBER OF CLAIMS:	39		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1233		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for purifying **Factor VIII:C** comprising contacting an immobilized antibody specifically binding a **Factor VIII:C** with **Factor VIII:C**, desorbing **Factor VIII:C** from the antibody which had adsorbed it, eluting **Factor VIII:C** from the presence of the antibody, passing the eluted **Factor VIII:C** through an affinity region capable of binding the **Factor VIII:C**, binding the **Factor VIII:C** in the affinity region and passing contaminants through said region, and eluting the purified **Factor VIII:C**.
C.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 34 OF 72 USPATFULL on STN

ACCESSION NUMBER: 95:25015 USPATFULL
TITLE: Solubilization and stabilization of factor VIII complex
INVENTOR(S): Bhattacharya, Prabir, Walnut, CA, United States
Motokubota, Toshiharu, Arcadia, CA, United States
PATENT ASSIGNEE(S): Alpha Therapeutic Corporation, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5399670		19950321 <--
APPLICATION INFO.:	US 1993-54903		19930429 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-876190, filed on 30 Apr 1992, now abandoned		
DOCUMENT TYPE:	Utility		

FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
ASSISTANT EXAMINER: Touzeau, Lynn
LEGAL REPRESENTATIVE: Christie, Parker & Hale
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 524

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for facilitating the reconstitution of lyophilized Factor VIII complex compositions, and compositions of Factor VIII complex, which are readily reconstituted. The process of the present invention comprises providing a purified Factor VIII complex ~~preparations~~; adding a stabilization agent comprising arginine; lyophilizing the stabilization agent-Factor VIII complex solutions; and reconstituting the lyophilized stabilization agent-Factor VIII complex by contacting it with solvent for less than one minute.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 35 OF 72 USPATFULL on STN

ACCESSION NUMBER: 94:91035 USPATFULL
TITLE: Gel filtration of factor VIII
INVENTOR(S): Brockway, William J., Oakland, CA, United States
Seng, Richard L., Guerneville, CA, United States
PATENT ASSIGNEE(S): Miles Inc., Berkeley, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5356878		19941018	<--
APPLICATION INFO.:	US 1993-852		19930104	(8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-587815, filed on 24 Sep 1990, now patented, Pat. No. US 5177591 which is a continuation of Ser. No. US 1987-135966, filed on 21 Dec 1987, now abandoned			

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
ASSISTANT EXAMINER: Touzeau, P. Lynn
LEGAL REPRESENTATIVE: Giblin, James A., Bradley, Bertram
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 693

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Highly purified antihemophilic factor is produced by a process comprising a PEG precipitation step, a gel filtration step and a virus inactivation step. Al(OH).sub.3 adsorption and PEG precipitation carried out at room temperature allow processing to proceed directly to a gel filtration step.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 36 OF 72 USPATFULL on STN

ACCESSION NUMBER: 94:15877 USPATFULL
TITLE: ~~Factor viii~~ purification process
INVENTOR(S): Bhattacharva, Prabir, Walnut, CA, United States
Motokubota, Toshiharu, Arcadia, CA, United States
PATENT ASSIGNEE(S): Alpha Therapeutic Corporation, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5288853		19940222	<--
APPLICATION INFO.:	US 1992-876410		19920430	(7)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Schain, Howard R.			
ASSISTANT EXAMINER:	Touzeau, Lynn			

LEGAL REPRESENTATIVE: Christie, Parker & Hale
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 777

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided in accordance with the practice of this invention a process for separating Factor VIII complex from an impure protein fraction containing Factor VIII complex. An aqueous solution of the impure protein fraction containing Factor VIII complex is applied to a heparin-coupled chromatographic medium, to bind the Factor VIII complex to the medium. The Factor VIII is then recovered from the heparin-coupled chromatographic medium by elution with an aqueous solution comprising CaCl₂ and histidine. The recovered Factor VIII is further purified by precipitation with a solution comprising glycine and NaCl, and washing the resultant precipitate with a solution comprising histidine, glycine, and NaCl to provide a Factor VIII complex solution with a specific activity of about 70 to about 150 units/mg.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 37 OF 72 USPATFULL on STN

ACCESSION NUMBER: 94:3911 USPATFULL
TITLE: Antihemophilic factor stabilization
INVENTOR(S): Johnson, Alan J., 127 W. 12th St., New York, NY, United States 10011
Fulton, Anne J., 515 Avon Dr., East Windsor, NJ, United States 08520

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5278289		19940111	<--
APPLICATION INFO.:	US 1991-790390		19911112	(7)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Russel, Jeffrey E.			
LEGAL REPRESENTATIVE:	Darby & Darby			
NUMBER OF CLAIMS:	2			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)			
LINE COUNT:	756			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of recovering a purified and stabilized protein having antihemophilic factor activity (Factor VIII); from a biological sample containing Factor VIII, at least one destabilizing protease impurity, i.e. thrombin, and optionally one or more proprotease impurity, is provided. The biological sample is contacted with a protease removing and/or inhibiting agent, thereby inhibiting and/or removing the destabilizing protease impurity. The method provides increased yield and resolution of Factor VIII. Also provided are purified and stabilized Factor VIII non-lyophilized, liquid in compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 38 OF 72 USPATFULL on STN

ACCESSION NUMBER: 93:93445 USPATFULL
TITLE: Process for the purification of factor VIII and factor VIII obtained by said process
INVENTOR(S): Arrighi, Silvana, Rieti, Italy
Borri, Maria G., Siena, Italy
Ceccarini, Costante, Castelnuovo Berardenga, Italy
PATENT ASSIGNEE(S): SCLAVO S.p.A., Siena, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5259951		19931109	<--
APPLICATION INFO.:	US 1991-713071		19910611	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1990-20610	19900612
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dawson, Robert A.	
ASSISTANT EXAMINER:	Kim, Sun Uk	
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	307	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for the purification of Factor VIII from human plasma is described, wherein a solution comprising Factor VIII is purified by using ion exchange chromatographic columns. Factor VIII obtained by said method is also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 39 OF 72 USPATFULL on STN
 ACCESSION NUMBER: 93:76632 USPATFULL
 TITLE: Method for isolating factors VIII from plasma by gel filtration chromatography under group separation conditions
 INVENTOR(S): Kaersgaard, Per, Vedbaek, Denmark
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5245014		19930914	<--
APPLICATION INFO.:	US 1990-610480		19901107	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1989-5621	19891109
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wax, Robert A.	
ASSISTANT EXAMINER:	Ekstrom, Richard C.	
LEGAL REPRESENTATIVE:	Zelson, Steve T., Lambiris, Elias J.	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	598	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for isolating Factor VIII from other proteins dissolved in blood plasma is disclosed, wherein plasma is subjected to gel filtration under group separation conditions giving a fraction containing Factor VIII in very high yield and almost free of other proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 40 OF 72 USPATFULL on STN
 ACCESSION NUMBER: 93:27199 USPATFULL
 TITLE: Method for purifying factor VIII: C, von Willebrand factor and complexes thereof
 INVENTOR(S): Kumar, Anur A., Seattle, WA, United States
 Hagen, Frederick S., Seattle, WA, United States
 Sledziewski, Andrzej Z., Seattle, WA, United States
 PATENT ASSIGNEE(S): ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5200510		19930406	<--
APPLICATION INFO.:	US 1988-162877		19880302	(7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1987-62896, filed on 16 Jun 1987, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Wax, Robert A.

ASSISTANT EXAMINER: Furman, Keith C.

LEGAL REPRESENTATIVE: Seed and Berry

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 626

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for purifying **factor VIII:C**, von Willebrand factor (vWF) or complexes thereof from heterogeneous biological fluids are disclosed. The methods utilize a binding peptide, specific to either **factor VIII:C** or vWF, bound to an insoluble matrix. Peptides suitable for use within the methods are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 41 OF 72 USPATFULL on STN

ACCESSION NUMBER: 93:5245 USPATFULL

TITLE: Method for the treatment of bleeding disorders

INVENTOR(S): Hedner, Ulla K. E., Bagangsvagen 29, SE-21620 Malmo, Sweden

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5180583		19930119	<--
APPLICATION INFO.:	US 1991-666423		19910308	(7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1989-368967, filed on 19 Jun 1989, now abandoned which is a continuation of Ser. No. US 1986-933408, filed on 20 Nov 1986, now abandoned			

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1985-5446	19851126
	DK 1986-459285	19860926
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Stone, Jacqueline	
LEGAL REPRESENTATIVE:	Zelson, Steve T., Lambiris, Elias J.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	463	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors, as well as a novel composition for use in treating bleeding disorders as disclosed. The method includes administering to a patient a composition comprising an effective haemostatic amount of factor VIIa, and is particularly effective in treating patients suffering from thrombocytopenia and von Willebrand's disease, as well as other platelet disorders. A composition suitable for use in treating such bleeding disorders comprises purified factor VIIa in a concentration of at least 25 µg/ ml.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 42 OF 72 USPATFULL on STN

ACCESSION NUMBER: 93:1491 USPATFULL

TITLE: Gel filtration of factor VIII

INVENTOR(S): Brockway, William J., Oakland, CA, United States
Seng, Richard L., Guerneville, CA, United States

PATENT ASSIGNEE(S): Miles, Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5177191		19930105 <--
APPLICATION INFO.:	US 1990-587815		19900924 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1987-135966, filed on 21 Dec 1987, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cashion, Jr., Merrell C.		
ASSISTANT EXAMINER:	Touzeau, P. Lynn		
LEGAL REPRESENTATIVE:	Aston, David J., Bradley, Bertram, Giblyn, James A.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
LINE COUNT:	683		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Highly purified antihemophilic factor can be produced from a cryoprecipitate by a process comprising a PEG precipitation step, a viral inactivation step and a gel filtration step, all steps being carried out at room temperature.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 43 OF 72 JICST-EPlus COPYRIGHT 2005 JST on STN

ACCESSION NUMBER: 930674621 JICST-EPlus

TITLE: Effect of Substrate and Diluent for Factor VIII Activity in Highly Purified Factor VIII **Concentrate** and Patient Plasma Infused Factor VIII **Concentrate**.

AUTHOR: TAKAHASHI ISAO; FURUTA MOTOMU; MIZUNO SHIN'ICHI; KAMIYA TADASHI
TAKAMATSU JUNKI

CORPORATE SOURCE: Aichi Red Cross Blood Center
Nagoya Univ., School of Medicine

SOURCE: Rinsho Byori (Japanese Journal of Clinical Pathology), (1993) vol. 41, no. 7, pp. 825-830. Journal Code: Z0687A (Fig. 1, Tbl. 3, Ref. 8)
CODEN: RBYOAI; ISSN: 0047-1860

PUB. COUNTRY: Japan

DOCUMENT TYPE: Journal; Article

LANGUAGE: Japanese

STATUS: New

AB We studied the difference between congenital factor VIII deficient plasma and factor VIII immunodepleted plasma on the effect of predilution for factor VIII activity determined by the one-stage assay. When standard curves of one-stage assay for **factor VIII: C** by GEORGE KING factor VIII deficient plasma (frozen at -80.DEG.C.), BEHRING factor VIII deficient plasma (lyophilized), DADE factor VIII depleted plasma (lyophilized, von **Willebrand factor** antigen 0.2 U/ml) and DADE factor VIII depleted plasma (lyophilized, von **Willebrand factor** antigen 1.0 U/ml) were compared, the difference between the clotting times for 100% and 6.25% of activity in each reagent were 39.5, 29.5, 25.0, 23.0 seconds respectively. Potency values in **concentrates** without albumin or von **Willebrand factor** showed a discrepancy between predilution in Owren-Koller buffer and predilution in factor VIII deficient plasma. Potencies of those products prediluted in Owren-Koller buffer were 40-60% lower than potencies prediluted in factor VIII deficient plasma. These results showed substrate and prediluent must be chosen carefully for the accurate assay of factor VIII activity in vitro for the highly purified factor VIII **concentrates**. (author abst.)

L3 ANSWER 44 OF 72 USPATFULL on STN

ACCESSION NUMBER: 92:63798 USPATFULL

TITLE: Method for evaluating immunogenicity

INVENTOR(S): Esmon, Pamela C., Richmond, CA, United States
Fournel, Michael A., Castro Valley, CA, United States

PATENT ASSIGNEE(S): Miles Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5135874		19920804	<--
APPLICATION INFO.:	US 1990-493659		19900315	(7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1988-202177, filed on 1 Jun 1988			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Kepplinger, Esther L.			
ASSISTANT EXAMINER:	Bidwell, Carol E.			
LEGAL REPRESENTATIVE:	Aston, David J., Enayati, Elizabeth F.			
NUMBER OF CLAIMS:	6			
EXEMPLARY CLAIM:	2			
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 8 Drawing Page(s)			
LINE COUNT:	897			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for evaluating the potential immunogenicity of a protein derived from recombinant DNA technology. The method involves injecting an animal with the recombinant protein and then isolating antiserum from the animal. The antiserum is depleted of antibodies to a reference protein, i.e., a plasma derived protein, by adsorbing the antiserum against the reference protein. The adsorbed antiserum is then blotted against the recombinant protein, to see if any antibodies were produced which recognize the recombinant protein, but did not recognize the plasma-derived protein during adsorption.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 45 OF 72 USPATFULL on STN
 ACCESSION NUMBER: 92:36292 USPATFULL
 TITLE: Factor VIII complex purification using heparin affinity chromatography
 INVENTOR(S): Kosow, David P., Monrovia, CA, United States
 Bhattacharya, Prabir, Walnut, CA, United States
 Sternburg, Charles F., Norco, CA, United States
 PATENT ASSIGNEE(S): Alpha Therapeutic Corporation, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5110907		19920505	<--
APPLICATION INFO.:	US 1989-388254		19890801	(7)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Wax, Robert A.			
ASSISTANT EXAMINER:	Ekstrom, Richard C.			
LEGAL REPRESENTATIVE:	Christie, Parker & Hale			
NUMBER OF CLAIMS:	15			
EXEMPLARY CLAIM:	1			
LINE COUNT:	842			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided in accordance with the practice of this invention, a process for separating Factor VIII complex from an impure protein fraction containing Factor VIII complex. An aqueous solution of the impure protein fraction containing Factor VIII complex is applied to a heparin coupled chromatographic medium to bind the Factor VIII complex to the medium. The Factor VIII is then recovered from the heparin coupled chromatographic medium by elution with an aqueous CaCl₂ solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 46 OF 72 USPATFULL on STN
 ACCESSION NUMBER: 92:14989 USPATFULL
 TITLE: Agent for the therapy of factor VIII-resistant hemophilia A, and a process for the preparation thereof
 INVENTOR(S): Heimburger, Norbert, Marburg, Germany, Federal Republic

of
Wenz, Karlheinz, Weimar, Germany, Federal Republic of
Wormsbacher, Wilfried, Kirchhain, Germany, Federal
Republic of
PATENT ASSIGNEE(S): Behringwerke Aktiengesellschaft, Marburg/Lahn, Germany,
Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5091363		19920225	<--
APPLICATION INFO.:	US 1988-230717		19880810	(7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1987-76600, filed on 22 Jul 1987, now abandoned			

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1986-3625090	19860724
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rosen, Sam	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett, and Dunner	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	335	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An agent for the therapy of hemophilia A which is resistant to treatment with factor VIII is described, and is obtainable by maintaining a mixture of factor VIII, antithrombin III, a phospholipid and calcium ions in an aqueous solution at a temperature of from 1° to 45° C. for at least one minute, adding factor IX, and maintaining the solution at a temperature offrom 1° to 45° C. until addition of a sample of this solution to an inhibitor plasma results in a partial thromboplastin time (PTT) of 15 to 30 seconds, where appropriate adding a polyol and, where appropriate, an amino acid, and, where appropriate, drying the solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 47 OF 72 USPATFULL on STN
ACCESSION NUMBER: 91:44553 USPATFULL
TITLE: Process for the **preparation** of factor VIII:C-deficient plasma, and a deficient plasma obtained in this way
INVENTOR(S): Becker, Udo, Munchen, Germany, Federal Republic of
Heimbürger, Norbert, Marburg, Germany, Federal Republic of
Braun, Konrad, Ebsdorfergrund, Germany, Federal Republic of
PATENT ASSIGNEE(S): Behringwerke Akitengesellschaft, Marburg, Germany,
Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5021243		19910604	<--
APPLICATION INFO.:	US 1988-164486		19880304	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3707213	19870306
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Robinson, Douglas W.	
ASSISTANT EXAMINER:	Witz, Jean	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett, and Dunner	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	

LINE COUNT: 254
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the **preparation** of a **factor VIII:C**-deficient plasma is made available, in which a starting plasma is consecutively treated with antibodies against von **Willebrand factor** and antibodies against factor VIII:Ag. The deficient plasma prepared in this way contains less than 0.5% residual activity of **factor VIII:C**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 48 OF 72 USPATFULL on STN
ACCESSION NUMBER: 91:1247 USPATFULL
TITLE: Lectin affinity chromatography of factor VIII
INVENTOR(S): Tsay, Grace C., Walnut Creek, CA, United States
PATENT ASSIGNEE(S): Miles Inc., Elkhart, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4981951		19910101	<--
APPLICATION INFO.:	US 1988-181001		19880414	(7)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Moskowitz, Margaret			
ASSISTANT EXAMINER:	Furman, Keith C.			
LEGAL REPRESENTATIVE:	Aston, David J., Bradley, Bertram			
NUMBER OF CLAIMS:	6			
EXEMPLARY CLAIM:	1			
LINE COUNT:	405			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of purifying a recombinant protein from a solution, such as tissue culture fluid, containing glycoproteins. The affinity of lectins for specific glycoproteins is assessed and used to select a particular lectin specific for the contaminating glycoprotein(s). A sugar buffer such as alpha methyl mannoside prevents binding of the recombinant protein. The preferred lectin is lentil lectin, for use in separating recombinant Factor VIII from tissue culture fluid contaminated with rodent protein from the cell line used to produce the recombinant Factor VIII.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 49 OF 72 USPATFULL on STN
ACCESSION NUMBER: 90:67728 USPATFULL
TITLE: Method for purifying antihemophilic factor
INVENTOR(S): Mathews, Rita W., New York, NY, United States
Johnson, Alan J., New York, NY, United States
PATENT ASSIGNEE(S): New York University, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4952675		19900828	<--
APPLICATION INFO.:	US 1988-291516		19881229	(7)
DISCLAIMER DATE:	20050510			
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1987-122372, filed on 19 Nov 1987, now patented, Pat. No. US 4847362 which is a continuation of Ser. No. US 1985-697267, filed on 1 Feb 1985, now patented, Pat. No. US 4743680			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Nutter, Nathan M.			
LEGAL REPRESENTATIVE:	Darby & Darby			
NUMBER OF CLAIMS:	11			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)			
LINE COUNT:	1197			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods for purifying proteins including AHF by column chromatography in the presence of additives including sugars and polyhydric alcohols which serve to increase the electrostatic forces on the surface of said proteins while decreasing the hydrophobicity of said proteins resulting in **preparations** of such proteins of high purity and/or resolution and/or recovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 50 OF 72 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 1990-255000 [34] WPIDS
DOC. NO. NON-CPI: ~~N~~1990-197573
DOC. NO. CPI: C1990-110404
TITLE: Production of von Willebrand factor
concentrates - by cleaving factor Vlll C complex
on anion exchanger.
DERWENT CLASS: B04 D16 P34
INVENTOR(S): HEIMBURGER, N; KUMPE, G; WELLNER, K
PATENT ASSIGNEE(S): (BEHW) BEHRINGWERKE AG; (CENT-N) CENTEON PHARMA GMBH;
(AVET) AVENTIS BEHRING GMBH
COUNTRY COUNT: 21
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
DE 3904354	A	19900816	(199034)*		5<--
EP 383234	A	19900822	(199034)		<--
R: AT BE CH DE ES FR GB GR IT LI LU NL SE					
AU 9049339	A	19900830	(199042)		<--
PT 93128	A	19900831	(199043)		<--
CA 2009946	A	19900814	(199044)		<--
JP 02264799	A	19901029	(199049)		<--
AU 638969	B	19930715	(199335)		<--
EP 383234	B1	19941130	(199501)	GE	8<--
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
DE 59007785	G	19950112	(199507)		<--
ES 2066020	T3	19950301	(199515)		<--
IE 65920	B	19951129	(199606)		<--
JP 2930243	B2	19990803	(199936)		6<--
KR 149999	B1	19980817	(200022)		<--
CA 2009946	C	20000411	(200035)	EN	<--
US 6239261	B1	20010529	(200132)		<--

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
DE 3904354	A	DE 1989-3904354	19890214
EP 383234	A	EP 1990-102716	19900212
JP 02264799	A	JP 1990-29777	19900213
AU 638969	B	AU 1990-49339	19900213
EP 383234	B1	EP 1990-102716	19900212
DE 59007785	G	DE 1990-507785	19900212
		EP 1990-102716	19900212
ES 2066020	T3	EP 1990-102716	19900212
IE 65920	B	IE 1990-511	19900213
JP 2930243	B2	JP 1990-29777	19900213
KR 149999	B1	KR 1990-1674	19900212
CA 2009946	C	CA 1990-2009946	19900213
US 6239261	B1	US 1990-478640	19900212
	Cont of	US 1991-759983	19910916
	Cont of	US 1992-899936	19920617
	Cont of	US 1994-253232	19940602

FILING DETAILS:

PATENT NO	KIND	PATENT NO
-----------	------	-----------

AU 638969	B Previous Publ.	AU 9049339
DE 59007785	G Based on	EP 383234
ES 2066020	T3 Based on	EP 383234
JP 2930243	B2 Previous Publ.	JP 02264799

PRIORITY APPLN. INFO: DE 1989-3904354 19890214

AN 1990-255000 [34] WPIDS

AB DE 3904354 A UPAB: 19930928

Production of von Willestrand factor (vWF) **concentrates** from starting materials containing vWF as a complex with **factor (VIII):c** is effected by (a) preparing a solution containing the starting material and 5-30 weight % of a carbohydrate in an amino acid buffer with a pH of 5.5-6.5 and (b) treating the solution with an anion exchanger capable of binding **factor (VIII):c** thereby obtg. a VWF solution

USE/ADVANTAGE - The **concentrates** are useful for treating von Willebrand's syndrome. The process gives high yields of high-purity vWF solns. which may be pasteurised to inactivate viruses.

0/0

ABEQ EP 383234 B UPAB: 19950110

A process for the **preparation** of pasteurised von **Willebrand factor concentrate**, which comprises a solution which contains von **Willebrand factor (vWF)** as complex with V III:C in a buffer of pH 5.5 to 6.5, which contains calcium and amino acids and has a carbohydrate concentration of 5-30% w/w, being treated with an anion exchanger to which F VIII:C binds, and the von **Willebrand factor concentrate** being obtd. from the soln.
Dwg.0/0

L3 ANSWER 51 OF 72 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN

ACCESSION NUMBER: 1990-09347 BIOTECHDS

TITLE: Recombinant Factor-VIII production - cloning, clinicals, and commercial production;

Factor-VIII:c and human recombinant von **Willebrand factor preparation** by mammal cell culture in serum-free culture medium; process monitoring, systems control and validation (conference abstract)

AUTHOR: Adamson S R

CORPORATE SOURCE: Genetics-Inst.

LOCATION: Genetics Institute, One Burtt Road, Andover, MA 01810, USA.

SOURCE: Abstr.Pap.Am.Chem.Soc.; (1990) 199 Meet., Pt.1,

BIOT80

CODEN: ACSRAL

DOCUMENT TYPE: Journal

LANGUAGE: English

AN 1990-09347 BIOTECHDS

AB Hemophilia A is a sex-linked bleeding disorder caused by a deficiency or abnormality of the blood-clotting protein **Factor-VIII :c**. The available therapy (plasma **concentrate**) is costly and associated with a finite risk of viral infections. The molecular cloning of **Factor-VIII:c** signaled the provision of pure **Factor-VIII:c**. Subsequently, **Factor-VIII:c** was produced by recombinant mammal cells in the presence of high concentrations (10-20% v/v) of animal serum, but not in serum-free culture media. The essential component of serum was identified as von **Willebrand factor (vWF)**. The requirement for serum can be eradicated by the addition of high concentrations of phospholipid vesicles to the culture medium, or by the co-expression of human vWF and **Factor-VIII:c** from the same recombinant cell. Development of these techniques was described with respect to strategies used in process monitoring, control and validation. These strategies are essential in order to address scientific and regulatory requirements or concerns directed towards assuring the production of high quality, safe products.
(1 ref)

ACCESSION NUMBER: 1989:530280 CAPLUS
 DOCUMENT NUMBER: 111:130280
 TITLE: Fluoroplastic immunoaffinity columns for purification of blood proteins
 INVENTOR(S): Zimmerman, Theodore S.; Fulcher, Carol A.
 PATENT ASSIGNEE(S): Scripps Clinic and Research Foundation, USA
 SOURCE: U.S., 5 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4831118	A	19890516	US 1987-83670	19870807 <--
PRIORITY APPLN. INFO.:			US 1987-83670	19870807

AB A protein purification column comprises a fluoroplastic substrate matrix having low reactivity to proteins, said matrix being capable of maintaining monoclonal antibodies attached thereto in an external configuration and preventing interaction with the protein to be bound to the antibody, and a monoclonal antibody attached to the substrate, the monoclonal antibody having a specific affinity for the protein to be isolated. Specific protein is isolated and purified from a solution by: (1) attaching protein-specific monoclonal antibody to the fluoroplastic substrate matrix to form an antibody-substrate conjugate; and (2) contacting protein to be isolated, in an appropriate buffer solution, with the antibody-substrate conjugate. An appropriate buffer may be applied to remove nonantibody-bound contaminants, followed by an appropriate eluting agent to remove the protein from the monoclonal antibody. Blood-coagulation factor VIII was purified from reconstituted Armour Factorate conc . by affinity chromatog. on perfluorocarbon support containing .apprx.2 mg anti-von Willebrand Factor monoclonal antibody 2.2.9/mL. The factor was eluted from the column with 0.35 M CaCl2 buffer. Total protein recovery was 95% (85% in eluate, 10% in pass-through and wash) when a slow flow rate (2.2 mL/min loading, 2.3 and 0.7 mL/min washing) was used.

ACCESSION NUMBER: 89:56511 USPATFULL
 TITLE: Method for purifying antihemophilic factor
 INVENTOR(S): Mathews, Rita W., both New York, NY, United States
 Johnson, Alan J., both New York, NY, United States
 PATENT ASSIGNEE(S): New York University, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4847362		19890711 <--
APPLICATION INFO.:	US 1987-122372		19871119 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1985-697267, filed on 1 Feb 1985, now patented, Pat. No. US 4743680		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kight, John		
ASSISTANT EXAMINER:	Nutter, Nathan M.		
LEGAL REPRESENTATIVE:	Darby & Darby		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1215		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a high-recovery, high-resolution method for purifying antihemophilic factor by using column chromatography techniques in the presence of sugars, polyhydric alcohols, amino acids or salts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 54 OF 72 USPATFULL on STN

ACCESSION NUMBER: 89:1286 USPATFULL

TITLE: Phospholipid affinity purification of **Factor VIII:C**

INVENTOR(S): Brown, James E., Lafayette, CA, United States
Cowgill, Cynthia A., Berkeley, CA, United States

PATENT ASSIGNEE(S): Miles Laboratories, Inc., Elkhart, IN, United States
(U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4795806		19890103	<--
APPLICATION INFO.:	US 1987-74123		19870716	(7)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Schain, Howard E.			
ASSISTANT EXAMINER:	Kushan, Jeff P.			
LEGAL REPRESENTATIVE:	Aston, David J., Simonton, Pamela A.			
NUMBER OF CLAIMS:	11			
EXEMPLARY CLAIM:	1			
LINE COUNT:	449			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Affinity purification of **Factor VIII:C**, both plasma derived and genetically engineered, using coupled phosphatidylserine (PS) as the predominant phospholipid (PH) results in a high degree of purity of **Factor VIII:C**, similar to that previously demonstrated with monoclonal antibodies specific to either **Factor VIII:C** or von **Willebrand factor**. Phospholipids that can be used in combination with PS are phosphatidylcholine (PC) and phosphatidylethanolamine (PE).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 55 OF 72 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 1990-007450 [01] WPIDS

DOC. NO. CPI: C1990-003204

TITLE: Separation of plasma proteins, especially factor-VIII - by chromatography on moderately ionic anion-exchange resin.

DERWENT CLASS: B04 J01

INVENTOR(S): BURNOUF, M; BURNOUF, T; BURNOUF-RADOSEVICH, M

PATENT ASSIGNEE(S): (REGI-N) CENT REGIONAL TRANSFUSION SANGUINE; (TRAN-N) CENT REGION TRANSFU; (REGI-N) CENT REGIONAL TRANS; (TRAN-N) CENT REG TRANSFUSION SANGUINE LILLE

COUNTRY COUNT: 22

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 8912065	A	19891214	(199001)*	FR	19<--
RW: AT BE CH DE FR GB IT LU NL SE					
W: AU DK FI JP KR NO SU US					
FR 2632309	A	19891208	(199005)		<--
AU 8930682	A	19900105	(199012)		<--
EP 359593	A	19900321	(199012)	FR	<--
R: AT BE CH DE ES FR GB GR IT LI LU NL SE					
FI 9000397	A	19900125	(199018)		<--
NO 9000529	A	19900507	(199024)		<--
DK 9000299	A	19900328	(199027)		<--
JP 03501974	W	19910509	(199125)		<--
AU 9211383	A	19920514	(199228)		<--
US 5252709	A	19931012	(199342)		5<--
SU 1837880	A3	19930830	(199519)		6<--
EP 359593	B1	19950426	(199521)	FR	10<--
R: AT BE CH DE ES FR GB GR IT LI LU NL SE					

NO 177188	B	19950424 (199522)	<--
DE 68922358	E	19950601 (199527)	<--
ES 2070919	T3	19950616 (199531)	<--
FI 96210	B	19960215 (199611)	<--
JP 2805364	B2	19980930 (199844)	6<--
KR 9710923	B1	19970702 (199946)	<--
CA 1340742	C	19990914 (200004)	FR <--
EP 359593	B2	20040107 (200405)	FR

R: AT BE CH DE ES FR GB GR IT LI LU NL SE

DK 2004000872	A	20040603 (200443)
DK 175322	B	20040823 (200456)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 8912065	A	WO 1989-FR50	19890208
FR 2632309	A	FR 1988-7530	19880607
EP 359593	A	EP 1989-400348	19890208
JP 03501974	W	JP 1989-502342	19890208
AU 9211383	A	AU 1992-11383	19920303
	Div ex	AU 1989-30682	
US 5252709	A	WO 1989-FR50	19890208
		US 1990-460972	19900406
SU 1837880	A3	WO 1989-FR50	19890208
		SU 1990-4743107	19900206
EP 359593	B1	EP 1989-400348	19890208
NO 177188	B	WO 1989-FR50	19890208
		NO 1990-529	19900205
DE 68922358	E	DE 1989-622358	19890208
		EP 1989-400348	19890208
ES 2070919	T3	EP 1989-400348	19890208
FI 96210	B	WO 1989-FR50	19890208
		FI 1990-397	19900125
JP 2805364	B2	JP 1989-502342	19890208
		WO 1989-FR50	19890208
KR 9710923	B1	WO 1989-FR50	19890208
		KR 1990-700239	19900206
CA 1340742	C	CA 1989-590961	19890214
EP 359593	B2	EP 1989-400348	19890208
DK 2004000872	A	DK 2004-872	20040603
DK 175322	B	WO 1989-FR50	19890208
		DK 1990-299	19900206

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 5252709	A Based on	WO 8912065
NO 177188	B Previous Publ.	NO 9000529
DE 68922358	E Based on	EP 359593
ES 2070919	T3 Based on	EP 359593
JP 2805364	B2 Previous Publ.	JP 03501974
	Based on	WO 8912065
DK 175322	B Previous Publ.	DK 9000299

PRIORITY APPLN. INFO: FR 1988-7530 19880607

AN 1990-007450 [01] WPIDS

AB WO 8912065 A UPAB: 19960520

Separation of human or animal plasma proteins is effected by chromatographing a solubilised cryoprecipitate fraction on a moderately ionic anion-exchange resin, such that very large mols. may be retained and hydrophobic interactions come into play, and recovering each of the proteins selectively by increasing the ionic strength of the elution buffer.

USE/ADVANTAGE - The process is capable of producing a factor VIII concentrate with a specific activity above 100 IU/mg, useful for treating type-A haemophilia, as well as fibrinogen, von Willebrand factor (vWF) and fibronectin concentrates requiring

further purificn.

Dwg. 0/0

Dwg. 0/0

ABEQ US 5252709 A UPAB: 19931202

Factor VIII is sepd. from plasma also contg. von willebrand's factor (VWF), fibrinogen and fibronectin by (A) chromatographing a buffer and a solubilised fraction of cryoprecipitated plasma on an exchange column having a DEAE gp. fixed to a vinyl polymer type gel, i.e. Fractogel TSK, which absorbs factor VIII, VWF and fibronectin and allows fibrinogen to pass into a 1st eluate, (B) increasing the ionic strength of the buffer to allow fibronectin and VWF to pass into a 2nd eluate and (C) further increasing the ionic strength of the buffer to allow elution of factor VIII.

The specific activity of **factor VIII:C** in the initial fraction is at least 0.1 UV.mg. The initial fraction has pref. been pre-purified by treatment with $Al(OH)_3$, cooling to 14-16 deg. C, centrifuging and recovery of the superntant. The buffer contains 2-4 g/ltr lysine and 8-11 g/ltr glycine and 0.11M NaCl. The ionic strength in (B) is increased by raising the NaCl concentration to 0.15 M and in (C) to 0.25. A virus inactivating treatment is also carried out on the plasma prior to chromatographing.

ADVANTAGE - The desired protein can be separated using a single chromatography column avoiding expensive and cumbersome further purification, which can decrease the activity of the protein, VWF, fibronectin and fibrinogen can be recovered separately.

Dwg. 0/0

ABEQ EP 359593 B UPAB: 19950602

Process for the separation of human or animal plasma proteins and for the **preparation of concentrates** of the said proteins for therapeutic use, characterised in that it comprises the following steps: the cryoprecipitate fraction of plasma, consisting essentially of fibrinogen, fibronectin, Willebrand's factor and Factor VIII, is used as starting material; the cryoprecipitate, dissolved in aqueous solution, is subjected to a single separation by chromatography on an anion exchange resin of which the matrix is a gel of the macroreticular vinyl polymer type which, as a result of its hydrophobic and porous properties, is capable of retaining the Factor VIII-Willebrand's factor complex; and the different proteins are recovered selectively by successive increases in the ionic strength of the elution buffer.

Dwg. 0/0

L3 ANSWER 56 OF 72 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 1989:612495 CAPLUS

DOCUMENT NUMBER: 111:212495

TITLE: Comparison of the in vitro characteristics of von **Willebrand factor** in British and commercial factor VIII **concentrates**

AUTHOR(S): Lawrie, A. S.; Harrison, P.; Armstrong, A. L.; Wilbourn, B. R.; Dalton, R. G.; Savidge, G. F.

CORPORATE SOURCE: Rayne Inst., St. Thomas' Hosp., London, SE1 7EH, UK
SOURCE: British Journal of Haematology (1989), 73(1), 100-4

CODEN: BJHEAL; ISSN: 0007-1048

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Qual./quant. anal. of von **Willebrand factor** antigen

(vWf:Ag) in either heat or solvent/detergent-treated factor VIII **concs.**, used for hemophilia replacement therapy, was undertaken to assess their suitability for the treatment of von Willebrand's disease (vWD). For the 1st time, immunoaffinity purified vWf:Ag (Monoclate byproduct) was also evaluated by in vitro assessment. Potencies of vWf:Ag varied considerably but were consistently higher (28.9-420.5 iu/mL) than **factor VIII:C** (one-stage) activity (8.13-42.44 iu/mL). The functional activity of vWf was assessed by either ristocetin cofactor (vWf:RCo) or collagen binding methods (vWf:CBA) with typical vWf:RCo/vWf:Ag ratios ranging from 0.08 to 0.94. Multimeric anal. confirmed that in vitro biol. activity was dependent on the presence of the high mol. weight forms of vWf:Ag. A significant correlation between

vWf:RCo activity and collagen binding was observed in all of the **concs.** with the exception of the immunopurified product. Apparently, either NHS 8Y (mean wWfRCo/vWf:Ag = 0.9), Haemate P (mean vWf:RCo/vWf:Ag = 0.69), and high purity Octapharma V.I (vWf:RCo/vWf:Ag = 0.82) which contain medium/high mol. weight vWf:Ag multimers are likely to be the most cost-effective in the treatment of symptomatic severe vWD patients than other currently available **concs.**

L3 ANSWER 57 OF 72 USPATFULL on STN

ACCESSION NUMBER: 88:29502 USPATFULL
 TITLE: Method for purifying antihemophilic factor
 INVENTOR(S): Mathews, Rita W., New York, NY, United States
 Johnson, Alan J., New York, NY, United States
 PATENT ASSIGNEE(S): New York University, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4743680		19880510 <--
APPLICATION INFO.:	US 1985-697267		19850201 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kight, John		
ASSISTANT EXAMINER:	Nutter, Nathan M.		
LEGAL REPRESENTATIVE:	Darby & Darby		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1233		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods for purifying proteins including AHF by column chromatography in the presence of additives including sugars and polyhydric alcohols which serve to increase the electrostatic forces on the surface of said proteins while decreasing the hydrophobicity of said proteins resulting in **preparations** of such proteins of high purity and/or resolution and/or recovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 58 OF 72 MEDLINE on STN

ACCESSION NUMBER: 89187703 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 3149046
 TITLE: Factor VIII procoagulant protein interacts with phospholipid vesicles via its 80 kDa light chain.
 AUTHOR: Kemball-Cook G; Edwards S J; Sewerin K; Andersson L O; Barrowcliffe T W
 CORPORATE SOURCE: National Institute for Biological Standards and Control, Potters Bar, Herts, UK.
 SOURCE: Thrombosis and haemostasis, (1988 Dec 22) 60 (3) 442-6.
 Journal code: 7608063. ISSN: 0340-6245.
 PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198905
 ENTRY DATE: Entered STN: 19900306
 Last Updated on STN: 19900306
 Entered Medline: 19890501

AB In a previous report, we detailed fractionation of polyclonal human anti-**Factor VIII:C** into a component directed exclusively against the phospholipid-binding site on Factor VIII (PL-site antibody) and another directed at other sites (non-PL-site antibody). The location on the F.VIII molecule of its PL-binding site has now been studied by two different methods using this fractionated 125I-labelled anti-F.VIII:C Fab'. The first method was modified from that of Weinstein et al. (Proc Natl Acad Sci USA 1981; 78: 5137-41), involving electrophoresis of F.VIII peptide-125I-Fab' A/F.VIII immunocomplexes in

SDS-polyacrylamide gels. PL-site antibody reacted with F.VIII peptides of apparent Mr approximately 80 kDa and sometimes 160 kDa in plasma and **concentrate**, but not with larger peptides. Non-PL-site antibody, however, reacted with a range of peptides of apparent Mr 90 kDa to 280 kDa. In addition, when purified F.VIII containing heavy and light chains (HC + LC), and isolated LC peptides were analysed, PL-site antibody bound to LC peptides whereas non-PL-site antibody did not. The second method used the antibody pools in immunoradiometric assays (IRMA's) of purified F.VIII peptides. Both labels measured similar amounts of F.VIII:Ag in a sample of purified F.VIII containing both HC and LC; on assaying an HC **preparation**, however, PL-site label measured only 2% of F.VIII:Ag found by non-PL-site label, indicating that PL-binding sites are absent in HC **preparations**. These results indicate that F.VIII binds to PL via its 80 kDa light chain.

L3 ANSWER 59 OF 72 USPATFULL on STN

ACCESSION NUMBER: 87:45187 USPATFULL

TITLE: Isolation of human plasma procoagulant protein factor VIII from biological factors

INVENTOR(S): Herring, Steven W., San Dimas, CA, United States

PATENT ASSIGNEE(S): Alpha Therapeutic Corporation, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4675385		19870623	<--
APPLICATION INFO.:	US 1985-716456		19850327	(6)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Schain, Howard E.			
LEGAL REPRESENTATIVE:	Christie, Parker & Hale			
NUMBER OF CLAIMS:	25			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)			
LINE COUNT:	979			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A rapid and simple process for purifying human, bovine and porcine procoagulant protein Factor VIII on a large scale using sequential high performance size exclusion chromatography under, first, low salt concentration conditions and, second, under high salt concentration conditions from reconstituted commercial **Factor VIII :C** (complexed Factor VIII) **concentrate**. The chromatographic separation is carried out on a high performance size exclusion chromatographic column packed with porous beads having a particle size of from about 13 to about 35 microns, pore diameters of from about 500 to about 2000 Angstroms and a pore volume of from about 1.0 to about 1.8 ml per gram. The first chromatographic separation is carried in a buffered aqueous solution using the buffered aqueous solution as an eluant. The low molecular weight constituents (impurities) are separated from Factor VIII and the high molecular weight constituents (impurities). A second chromatographic separation may be carried out after Factor VIII has been dissociated in a buffered solution having a concentration of from about 0.25 to about 0.45M calcium ion. The second chromatographic column is packed with some packing as the first column and is eluted with a buffered aqueous solution containing 0.25 to 0.45M calcium ion. In a column of 2.5+60 cm, 4 gms of commercial Factor VIII **concentrate** can be purified in less than two hours. The process is amenable to scale up.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 60 OF 72 USPATFULL on STN

ACCESSION NUMBER: 87:39834 USPATFULL

TITLE: Isolation and culture of adrenal medullary endothelial cells producing blood clotting **factor VIII:C**

INVENTOR(S): Pollard, Harvey B., Potomac, MD, United States

Ornberg, Richard, Bethesda, MD, United States
 Banerjee, Dipak, Rockville, MD, United States
 Youdim, Moussa, Rockville, MD, United States
 Lelkes, Peter, Rockville, MD, United States
 Heldman, Eli, Rockville, MD, United States
 The United States of America as represented by the
 Secretary of the Department of Health and Human
 Services, Washington, DC, United States (U.S.
 government)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4670394		19870602
APPLICATION INFO.:	US 1984-672451		19841116 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wiseman, Thomas G.		
ASSISTANT EXAMINER:	Maurey, Karen		
LEGAL REPRESENTATIVE:	Holman & Stern		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 5. Drawing Page(s)		
LINE COUNT:	557		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention discloses a new line of endothelial cell of adrenal medullary origin capable of producing blood clotting
Factor VIII:C. A method of isolating and culturing said cell line has also been disclosed. **Factor VIII:C** is useful in treating hemophilia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 61 OF 72 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN

ACCESSION NUMBER: 87115012 EMBASE
 DOCUMENT NUMBER: 1987115012
 TITLE: Characteristics of a heat treated antihaemophilic cryoprecipitate.
 AUTHOR: Skjonsberg O.H.; Gravem K.; Kierulf P.; Godal H.C.
 CORPORATE SOURCE: Haematological Research Laboratory and Central Laboratory, Ulleval Hospital, 0407 Oslo 4, Norway
 SOURCE: Thrombosis Research, (1987) Vol. 45, No. 5, pp. 625-634.
 CODEN: THBRAA
 COUNTRY: United States
 DOCUMENT TYPE: Journal
 FILE SEGMENT: 037 Drug Literature Index
 025 Hematology
 022 Human Genetics
 030 Pharmacology
 LANGUAGE: English
 ENTRY DATE: Entered STN: 911211
 Last Updated on STN: 911211

AB In order to evaluate the influence of heat treatment (68°C for 24 or 72 hours) on the essential components of antihaemophilic cryoprecipitate, i.e. factor VIII coagulant activity (VIII:C), von Willebrand factor (VIII:Ag and VIII:RCF) and fibrinogen, ordinary lyophilized cryoprecipitate was compared to heat treated, aminoacid-enriched specimens. The median reduction in factors VIII:C, VIII:Ag, VIII:RCF and fibrinogen during lyophilization of ordinary cryoprecipitate was 26 per cent, 11 per cent, 1 per cent and 8.5 per cent, respectively. Heat treatment of such cryoprecipitate resulted in 85 to 98.5 per cent reduction in these parameters, while the reduction following lyophilization and heat treatment (24 hours) of aminoacid-containing preparations was not significantly different from non-heated, ordinary cryoprecipitate. Following heating of aminoacid-enriched cryoprecipitate for 72 hours, only factor VIII:RCF was significantly reduced (32.5 per cent) compared to non-heated samples. Ordinary

cryoprecipitate was almost insoluble following heat treatment. Enrichment with aminoacids, however, made the heat treated cryoprecipitate fully soluble, but the content of these vials were slightly slower in dissolving than non-heated **preparations**. Ultracentrifugation prior to lyophilization and heating did not improve the solubility. If heat treatment proves to be efficient in inactivating viral agents, we conclude that heated (68°C for 24 hours), aminoacid-enriched cryoprecipitate may be a convenient product for treating haemophilia A, von Willebrand's disease and hypofibrinogenemia.

L3 ANSWER 62 OF 72 USPATFULL on STN

ACCESSION NUMBER: 86:55170 USPATFULL

TITLE: Deglycosylated Human **Factor VIII**:

INVENTOR(S):
C
Chavin, Stephen I., Rochester, NY, United States
Fay, Philip J., Rochester, NY, United States

PATENT ASSIGNEE(S): University of Rochester, Rochester, NY, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4614795		19860930 <--
APPLICATION INFO.:	US 1984-570728		19840113 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1982-405456, filed on 5 Aug 1982, now patented, Pat. No. US 4495175		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kight, John		
ASSISTANT EXAMINER:	Nutter, Nathan M.		
LEGAL REPRESENTATIVE:	Hallenbeck, Robert M., LuKacher, Martin L., Gibblin, James		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	635		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Highly purified, biologically active Human **Factor VIII**:
:C having specific activities of about 4000-8000 units per milligram of protein is prepared. In the method of **preparation**, an AHF **concentrate** is solubilized or equilibrated in an aqueous medium and treated to change the effective Stokes' radius of the **Factor VIII**:C to an apparently low value and then subjected to a separation from the **concentrate**. Treatment of the highly purified **Factor VIII**:C with a mixture of glycosidases causes substantial removal of carbohydrate side chains without reduction of procoagulant activity and with retention of significant in vivo survival time.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 63 OF 72 USPATFULL on STN

ACCESSION NUMBER: 86:16911 USPATFULL

TITLE: ~~Purification~~ of factor VIII with insoluble matrix having free sulfate groups covalently bound thereto

INVENTOR(S):
Saundry, Richard H., London, England
Savidge, Geoffrey F., Kent, England

PATENT ASSIGNEE(S): The Special Trustees for St. Thomas' Hospital, London, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4578218		19860325 <--
APPLICATION INFO.:	US 1985-699957		19850208 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1984-3473	19840209
DOCUMENT TYPE:	Utility	

FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
LEGAL REPRESENTATIVE: Cushman, Darby & Cushman
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 765

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Factor VIII is purified by adsorption onto a insoluble matrix having free sulphate groups, such as dextran sulphate, and selective elution therefrom.

A suitable eluant for the purification of the von Willebrand protein (Factor VIIIIR:vWp) is citrate buffer, pH 6.85, containing 0.47 M sodium chloride and 2.14 mM calcium chloride.

A suitable eluant for the purification of the Factor VIII complex (Factor VIIIIR:Ag, Factor VIIIIR:vWp and **Factor VIII:** C) is citrate buffer at pH value between 6.2 and 7.3 containing 1.0 M glycine, 2.14 mM calcium chloride and 0.5 M sodium chloride at +4° C.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 64 OF 72 IFIPAT COPYRIGHT 2005 IFI on STN DUPLICATE 4

AN 01572348 IFIPAT;IFIUDB;IFICDB
TITLE: ~~PREPARATION~~ OF HIGHLY PURIFIED HUMAN
ANTIHEMOPHILIC FACTOR

INVENTOR(S): Chavin, Stephen I, Rochester, NY
Fay, Philip J, Rochester, NY
PATENT ASSIGNEE(S): University of Rochester, Rochester, NY
PRIMARY EXAMINER: Rosen, Sam
AGENT: Aston, David J
Leitereg, Theodore J

	NUMBER	PK	DATE
PATENT INFORMATION:	US 4495175	A	19850122
	(CITED IN 021 LATER PATENTS)		
APPLICATION INFORMATION:	US 1982-405456		19820805
EXPIRATION DATE:	5 Aug 2002		
FAMILY INFORMATION:	US 4495175		19850122
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	CHEMICAL		
	GRANTED		

MICROFILM REEL NO: 004119 FRAME NO: 0680

NUMBER OF CLAIMS: 10

GRAPHICS INFORMATION: 3 Drawing Sheet(s), 5 Figure(s).

AB Highly purified, biologically active Human Antihemophilic Factor (AHF) **preparations** are prepared having specific activities of about 4000-8000 units per milligram of AHF. In the method of **preparation** an AHF **concentrate**, prepared by fractionation of plasma to partially remove fibrinogen, fibronectin and other plasma components is subjected to a separation on the basis of Stokes' radius to separate AHF from the bulk of remaining proteins in the AHF **concentrate**. The pooled fractions containing AHF activity are concentrated by precipitation with ammonium sulfate, sodium sulfate, etc., by diafiltration, by PEG addition, or the like. The **concentrate**, is solubilized or equilibrated in an aqueous medium and treated to change the effective Stokes' radius of the AHF to an apparently low value and then subjected to a separation from the **concentrate**. The AHF pool from above is treated to remove cations by dialysis against an appropriate buffer of lower ionic strength and chromatographed on an anionexchange medium. The AHF fraction from the above chromatography, is a highly purified AHF **preparation**.

CLMN 10

GI 3 Drawing Sheet(s), 5 Figure(s).

L3 ANSWER 65 OF 72 USPATFULL on STN

ACCESSION NUMBER: 85:61585 USPATFULL

TITLE: Ultrapurification of factor VIII using monoclonal antibodies

INVENTOR(S): Zimmerman, Theodore S., La Jolla, CA, United States
Fulcher, Carol A., La Jolla, CA, United States

PATENT ASSIGNEE(S): Scripps Clinic and Research Foundation, La Jolla, CA,
United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 32011		19851022	<--
	US 4361509		19821130	(Original)
APPLICATION INFO.:	US 1983-563795		19831221	(6)
	US 1981-330105		19811214	(Original)
DOCUMENT TYPE:	Reissue			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Schain, Howard E.			
NUMBER OF CLAIMS:	36			
EXEMPLARY CLAIM:	30			
LINE COUNT:	715			
CAS INDEXING IS AVAILABLE FOR THIS PATENT.				
CAS INDEXING IS AVAILABLE FOR THIS PATENT.				

L3 ANSWER 66 OF 72 MEDLINE on STN

ACCESSION NUMBER: 85207837 MEDLINE

DOCUMENT NUMBER: PubMed ID: 3922990

TITLE: Standardization of factor VIII: establishment and use of secondary standards.

AUTHOR: Panicucci F; Angeloni G; Arrighi S; Bucci E; DiMambro G;
Lecchini L; Pitruzzello S; Positano M

SOURCE: Journal of biological standardization, (1985 Apr)
13 (2) 115-21.

Journal code: 0400335. ISSN: 0092-1157.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198507

ENTRY DATE: Entered STN: 19900320

Last Updated on STN: 19900320

Entered Medline: 19850725

AB Two secondary standards for use in routine assays of Factor VIII in therapeutic **concentrates** and in patients, plasmas, respectively, have been established in a multicenter collaborative study. In order to assess the effect of the adoption of these **preparations** as common Secondary Standards a comparative assay has been performed: one sample of a Factor VIII **concentrate** of intermediate purity and one plasma sample have been tested in two laboratories for **Factor VIII:C** activity using as reference, among others, the common working standard. Analysis of the results shows that with the plasma sample the differences of the estimates obtained with any of the references in our two laboratories were not statistically significant (P greater than 0.3), while with the **concentrate** sample the differences were always statistically significant (P less than 0.005). The study shows that the adoption of common working standards (besides the uniformity in assay method, reagents and basic equipment) is not sufficient to eliminate interlaboratory variation in the measurement of **Factor VIII:C**.

L3 ANSWER 67 OF 72 USPATFULL on STN

ACCESSION NUMBER: 84:51336 USPATFULL

TITLE: Heparin polyelectrolyte polymer complex

INVENTOR(S): Johnson, John H., Kirkwood, MO, United States

PATENT ASSIGNEE(S): Monsanto Company, St. Louis, MO, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 4471112 19840911 <--
APPLICATION INFO.: US 1983-460227 19830124 (6)
RELATED APPLN. INFO.: Division of Ser. No. US 1982-392929, filed on 28 Jun
1982, now patented, Pat. No. US 4397841
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Brown, Johnnie R.
LEGAL REPRESENTATIVE: Meyer, Scott J., Williams, Jr., James W.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 472

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A **concentrate** of blood coagulation **Factor VIII:C** is obtained in high yield by fractionation of blood plasma with a sequence of adsorption steps employing two different water-insoluble, cross-linked polyelectrolyte copolymers, each in the presence of exogenous heparin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 68 OF 72 USPATFULL on STN

ACCESSION NUMBER: 83:34248 USPATFULL
TITLE: Production of blood coagulation **factor VIII:C**

INVENTOR(S): Johnson, John H., Kirkwood, MO, United States
PATENT ASSIGNEE(S): Monsanto Company, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4397841		19830809	<--
APPLICATION INFO.:	US 1982-392929		19820628 (6)	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Rosen, Sam			
LEGAL REPRESENTATIVE:	Meyer, Scott J., Williams, Jr., James W.			
NUMBER OF CLAIMS:	9			
EXEMPLARY CLAIM:	1			
LINE COUNT:	504			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A **concentrate** of blood coagulation **Factor VIII:C** is obtained in high yield by fractionation of blood plasma with a sequence of adsorption steps employing two different water-insoluble, cross-linked polyelectrolyte copolymers, each in the presence of exogenous heparin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 69 OF 72 USPATFULL on STN

ACCESSION NUMBER: 82:57885 USPATFULL
TITLE: Ultrapurification of factor VIII using monoclonal antibodies
INVENTOR(S): Zimmerman, Theodore S., La Jolla, CA, United States
Fulcher, Carol A., La Jolla, CA, United States
PATENT ASSIGNEE(S): Scripps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4361509		19821130	<--
APPLICATION INFO.:	US 1981-330105		19811214 (6)	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Schain, Howard E.			
NUMBER OF CLAIMS:	16			
EXEMPLARY CLAIM:	1			
LINE COUNT:	596			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of preparing high purity procoagulant protein comprising the steps of (a) adsorbing a VIII:C/VIII:RP complex from a plasma or commercial **concentrate** source of factor VIII onto agarose beads bound to a monoclonal antibody specific to VIII:RP, (b) eluting VIII:C with a salt solution, (c) adsorbing the eluted VIII:C on an animohexyl agarose column and eluting the VIII:C with a salt solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 70 OF 72 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1982:213755 CAPLUS

DOCUMENT NUMBER: ~~96:213755~~

TITLE: Porcine **factor VIII:C**
prepared by affinity interaction with von
Willebrand factor and heterologous
antibodies: sodium dodecyl sulfate polyacrylamide gel
analysis

AUTHOR(S): Knutson, Gaylord J.; Fass, David N.

CORPORATE SOURCE: Mayo Clin. Mayo Found., Rochester, MN, 55905, USA

SOURCE: Blood (1982), 59(3), 615-24
CODEN: BLOOAW; ISSN: 0006-4971

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The concentration and partial purification of porcine **factor VIII:C** from plasma by conventional precipitation and chromatog. techniques was reported. Blood from heparinized animal(s) was collected in citrate, soybean trypsin inhibitor, ϵ -aminocaproic acid, and benzamidine. After Al(OH)₃ adsorption, polyethylene glycol-6000 precipitation, QAE-cellulose chromatog., and dextran sulfate-agarose chromatog, the **factor VIII:C conc.** was 8100-fold purified with an overall yield of 24%, and thrombin treatment of the **factor VIII:C** gave an activation coefficient of up to 56. The activation coefficient of plasma **factor VIII:C conc.** on von **Willebrand factor**-agarose produced a 2-fold increase in specific activity. This product was applied to a 2nd affinity resin, the acidic IgG fraction of human antihuman **factor VIII:C** coupled to agarose. The inactive material which eluted at pH 2.8 from this column and from a similarly prepared nonimmune IgG-agarose column was analyzed by SDS-polacrylamide gel electrophoresis (PAGE). The material uniquely eluted from the immune agarose was represented by protein bands with apparent mol. wts. of 166,000, 130,000, and 76,000 and also retained some remnant antigen activity in antibody neutralization studies. Thrombin activated **factor VIII:C** (40-fold) from von **Willebrand factor**-agarose chromatog. was also specifically bound only by the antifactor VIII:C-agarose. The inactive material which eluted from the antibody column contained polypeptides with apparent mol. wts. of 76,000, 67,000, and 50,000. Thus, the material purified by 2 different affinity reagents and visualized by the SDS-PAGE represents at least, in part, polypeptides derived from porcine **factor VIII:C**.

L3 ANSWER 71 OF 72 MEDLINE on STN

ACCESSION NUMBER: 82225663 MEDLINE

DOCUMENT NUMBER: ~~PubMed~~ ID: 6806984

TITLE: Control of large-scale plasma thawing for recovery of cryoprecipitate factor VIII.

AUTHOR: Foster P R; Dickson A J; McQuillan T A; Dickson I H; Keddie S; Watt J G

SOURCE: Vox sanguinis, (1982) 42 (4) 180-9.
Journal code: 0413606. ISSN: 0042-9007.

PUB. COUNTRY: Switzerland

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198208

ENTRY DATE: Entered STN: 19900317

Last Updated on STN: 19900317

Entered Medline: 19820826

AB Cryoprecipitation is commonly used as the primary step in the **preparation** of clinical factor VIII **concentrates**; yet recovery is usually very low. Much of this loss is due to poor temperature control and a process of continuous plasma thawing has been designed to overcome this. A substantial improvement has resulted, with an increase in both yield and purity of **factor VIII**:
C of over 50% in comparison to a conventional batch thaw process.

L3 ANSWER 72 OF 72 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 81209716 EMBASE

DOCUMENT NUMBER: 1981209716

TITLE: Kinetic analysis of bovine factor VIII in the hemophilic dog.

AUTHOR: Gentry P.A.; Kirby E.P.; Gentry R.D.

CORPORATE SOURCE: Dept. Biomed. Scis Mathemat. Statist., Univ. Guelph, Ontario, Canada

SOURCE: Thrombosis and Haemostasis, (1981) Vol. 46, No. 2, pp. 485-488.

CODEN: THHADQ

COUNTRY: Germany

DOCUMENT TYPE: Journal

FILE SEGMENT: 025 Hematology

LANGUAGE: English

ENTRY DATE: Entered STN: 911209

Last Updated on STN: 911209

AB Bovine factor VIII, which did not contain platelet aggregating factor activity, was infused into hemophilic dogs. Factor VIII procoagulant (VIII:C) levels in the dogs increased dramatically, then decreased in a biphasic manner. The half-life of the longest component was 3-7 hrs. The infusions were hemostatically effective and also caused a prolonged shortening of the activated partial thromboplastin time. These studies demonstrate that the platelet aggregating factor activity of bovine factor VIII is not essential for its maintenance in the circulation and that **preparations** lacking this activity may be clinically useful. When **concentrates** of partially purified **factor VIII**:C (essentially free of both platelet aggregating factor and factor VIII-related antigen) were infused, marked increases in VIII:C levels were also observed, but the half-life was significantly shorter (T1/2 of approximately 1 hr).

L6 ANSWER 1 OF 4 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN

ACCESSION NUMBER: 2004-14441 BIOTECHDS

TITLE:

Von Willebrand factor

concentrates containing **Factor VIII:**

C, having elevated high molecular multimer content and low immunogenicity, useful for treating hemophilia A and von Willebrand syndrome;

plasma or recombinant **Factor-VIII:**

c treatment for disease therapy

AUTHOR: KUMPE G; JURASCHEK M; MAYER N; SCHULTE S; WORMSBAECHER W

PATENT ASSIGNEE: AVENTIS BEHRING GMBH

PATENT INFO: EP 1405863 7 Apr 2004

APPLICATION INFO: EP 2003-20148 5 Sep 2003

PRIORITY INFO: DE 2002-1046125 1 Oct 2002; DE 2002-1046125 1 Oct 2002

DOCUMENT TYPE: Patent

LANGUAGE: German

AN 2004-14441 BIOTECHDS

AB DERWENT ABSTRACT:

NOVELTY - **Von Willebrand factor** (vWF)

concentrates (I) containing **Factor VIII:C**

(FVIII:C) are obtained by **fractional precipitation**

from a liquid containing FVIII:C and vWF; and have an elevated content of high molecular multimers of vWF and a ratio of vWF:RCoF (ristocetin cofactor) activity to vWF:Ag of more than 1, are new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for the preparation of (I).

ACTIVITY - Hemostatic.

MECHANISM OF ACTION - Blood coagulation factor.

USE - (I) are used in medicaments for treating hemophilia A and von Willebrand syndrome (claimed).

ADMINISTRATION - No details given in the source material.

ADVANTAGE - The high content of high molecular multimers of vWF reduces the immunogenicity of recombinant or plasma FVIII:C (claimed), and thus reduces side-effects. Optimal vWF/FVIII:C with enriched high molecular multimer content are obtainable in simple and targeted manner by selective precipitation. The coagulation-active FVIII:C is stabilized by the vWF, and the high content of high molecular multimers provides a more rapid hemostatic action.

EXAMPLE - A solution of 200 g cryoprecipitate in 800 ml 0.1 M sodium chloride-glycine solution was treated with 10 volume % of 1.5% aluminum hydroxide suspension, stirred for 15 minutes and centrifuged. The supernatant (820 ml) was stirred with sufficient glycine to precipitate the fibrinogen content and again centrifuged. The glycine-containing supernatant was treated under stirring with 15 % sodium chloride to precipitate the vWF/FVIII:C complex quantitatively. A solution of the precipitate in 64 ml sodium chloride-glycine buffer was stabilized with sucrose (1 g/ml) and glycine (150 g/l), pasteurized for 10 hours at 60 degreesC, cooled and diluted with an equal volume of sodium chloride-glycine buffer. The diluted solution (containing 1.6 g/l sodium chloride and 124.4 g/l glycine) was treated under stirring with a precipitation medium such that the precipitation mixture contained 80 g/l glycine and 122 g/l sodium chloride. After stirring for 45 minutes, the fine precipitate was removed by centrifugation. The obtained fraction (dissolved in isotonic buffer) was enriched in high molecular multimers, and had ratios of FVIII:C to vWF:RCoF of 1:2.4, FVIII:C to vWF:Ag of 1:0.7 and vWF:Ag to vWF:RCoF of 1:3.6. For comparison, the starting complex had ratios of FVIII:C to vWF:RCoF of 1:3.1, FVIII:C to vWF:Ag of 1:2.5 and vWF:Ag to vWF:RCoF of 1:1.2; and cryo-solution after aluminum hydroxide adsorption had ratios of FVIII:C to vWF:RCoF of 1:1.6, FVIII:C to vWF:Ag of 1:2.6 and vWF:Ag to vWF:RCoF of 1:0.6. (14 pages)

L6 ANSWER 2 OF 4 IFIPAT COPYRIGHT 2005 IFI on STN

AN 10625429 IFIPAT;IFIUDB;IFICDB

TITLE:

CONCENTRATE OF A FACTOR VIII:

C-CONTAINING VON WILLEBRAND

FACTOR AND THE PROCESS RELATING THERETO

INVENTOR(S):

Juraschek; Manfred, Weimar, DE

PATENT ASSIGNEE(S): Kumpe; Gerhardt, Wetter, DE
AGENT: Mayer; Natascha, Marburg, DE
Schulte; Stefan, Marburg, DE
Wormshabacher; Wilfried, Kirchhain, DE
Unassigned
Finnegan, Henderson, Farabow, ;Garrett & Dunner,
L.L.P., 1300 I Street, N. W., Washington, DC,
20005-3315, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2004132654	A1	20040708
APPLICATION INFORMATION:	US 2003-670563		20030926

	NUMBER	DATE
PRIORITY APPLN. INFO.:	DE 2002-102461252	20021001
FAMILY INFORMATION:	US 2004132654	20040708
DOCUMENT TYPE:	Utility	
	Patent Application - First Publication	
FILE SEGMENT:	CHEMICAL	
	APPLICATION	

NUMBER OF CLAIMS: 18
AB The invention relates to a concentrate and a process for producing a
factor VIII:C-containing von
Willebrand factor by fractional
precipitation from a liquid comprising factor
VIII:C and von Willebrand
factor, resulting in an increased content of high molecular
weight multimers of von Willebrand factor
and a ratio of the vWF:RCof activity to vWF:Ag of greater than 1.
CLMN 18

L6 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2004:172490 USPATFULL
TITLE: Concentrate of a factor VIII:

INVENTOR(S): C-containing von Willebrand
factor and the process relating thereto
Kumpe, Gerhardt, Wetter, GERMANY, FEDERAL REPUBLIC OF
Juraschek, Manfred, Weimar, GERMANY, FEDERAL REPUBLIC
OF
Mayer, Natascha, Marburg, GERMANY, FEDERAL REPUBLIC OF
Schulte, Stefan, Marburg, GERMANY, FEDERAL REPUBLIC OF
Wormshabacher, Wilfried, Kirchhain, GERMANY, FEDERAL
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004132654	A1	20040708
APPLICATION INFO.:	US 2003-670563	A1	20030926 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10246125	20021001
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	722	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a concentrate and a process for producing a
factor VIII:C-containing von
Willebrand factor by fractional
precipitation from a liquid comprising factor
VIII:C and von Willebrand

factor, resulting in an increased content of high molecular weight multimers of **von Willebrand factor** and a ratio of the vWF:RCoF activity to vWF:Ag of greater than 1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 4 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 2004-297054 [28] WPIDS

DOC. NO. CPI: C2004-113576

TITLE: **Von Willebrand factor**
concentrates containing **Factor VIII**
C, having elevated high molecular multimer content and low immunogenicity, useful for treating hemophilia A and von Willebrand syndrome.

DERWENT CLASS: B04 D16

INVENTOR(S): JURASCHEK, M; KUMPE, G; MAYER, N; SCHULTE, S;
WORMSBAECHER, W; WORMSHABACHER, W

PATENT ASSIGNEE(S): (AVET) AVENTIS BEHRING GMBH; (CENT-N) CENTEON PHARMA
GMBH; (JURA-I) JURASCHEK M; (KUMP-I) KUMPE G; (MAYE-I)
MAYER N; (SCHU-I) SCHULTE S; (WORM-I) WORMSHABACHER W

COUNTRY COUNT: 35

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 1405863	A1	20040407	(200428)*	GE	14
	R:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV			
		MC MK NL PT RO SE SI SK TR			
CA 2443463	A1	20040401	(200428)	EN	
DE 10246125	A1	20040415	(200428)		
JP 2004123744	A	20040422	(200428)		16
US 2004132654	A1	20040708	(200445)		
KR 2004030369	A	20040409	(200453)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 1405863	A1	EP 2003-20148	20030905
CA 2443463	A1	CA 2003-2443463	20030929
DE 10246125	A1	DE 2002-10246125	20021001
JP 2004123744	A	JP 2003-339076	20030930
US 2004132654	A1	US 2003-670563	20030926
KR 2004030369	A	KR 2003-68405	20031001

PRIORITY APPLN. INFO: DE 2002-10246125 20021001

AN 2004-297054 [28] WPIDS

AB EP 1405863 A UPAB: 20040429

NOVELTY - **Von Willebrand factor** (vWF)

concentrates (I) containing **Factor VIII:C**

(FVIII:C) are obtained by **fractional precipitation**

from a liquid containing FVIII:C and vWF; and have an elevated content of high molecular multimers of vWF and a ratio of vWF:RCoF (ristocetin cofactor) activity to vWF:Ag of more than 1, are new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for the preparation of (I).

ACTIVITY - Hemostatic.

MECHANISM OF ACTION - Blood coagulation factor.

USE - (I) are used in medicaments for treating hemophilia A and von Willebrand syndrome (claimed).

ADVANTAGE - The high content of high molecular multimers of vWF reduces the immunogenicity of recombinant or plasma FVIII:C (claimed), and thus reduces side-effects. Optimal vWF/FVIII:C with enriched high molecular multimer content are obtainable in simple and targeted manner by selective precipitation. The coagulation-active FVIII:C is stabilized by the vWF, and the high content of high molecular multimers provides a more rapid hemostatic action.

=> d his

(FILE 'HOME' ENTERED AT 11:04:28 ON 02 AUG 2005)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, ...' ENTERED AT 11:05:21 ON 02 AUG 2005

L1 98 S FACTOR VIII:C AND WILLEBRAND FACTOR AND CONCENTRATE AND PREPA
 L2 77 S L1 AND PY<2002
 L3 72 DUP REM L2 (5 DUPLICATES REMOVED)
 L4 0 S L3 AND ALKALI METAL AND (FRACTIONAL PRECIPITATION)
 L5 0 S L3 AND FRACTIONAL PRECIPITATION
 L6 4 S FRACTIONAL PRECIPITATION AND FACTOR VIII:C AND VON WILLEBRAND

=> s L6 and metal

40 FILES SEARCHED...

70 FILES SEARCHED...

L7 3 L6 AND METAL

=> d L7 1-3 ibib,abs

L7 ANSWER 1 OF 3 IFIPAT COPYRIGHT 2005 IFI on STN
 AN 10625429 IFIPAT;IFIUDB;IFICDB
 TITLE: ~~CONCENTRATE OF A FACTOR VIII:~~
C-CONTAINING VON WILLEBRAND
FACTOR AND THE PROCESS RELATING THERETO
 INVENTOR(S): Juraschek; Manfred, Weimar, DE
 Kume; Gerhardt, Wetter, DE
 Mayer; Natascha, Marburg, DE
 Schulte; Stefan, Marburg, DE
 Wormshabacher; Wilfried, Kirchhain, DE
 PATENT ASSIGNEE(S): Unassigned
 AGENT: Finnegan, Henderson, Farabow,;Garrett & Dunner,
 L.L.P., 1300 I Street, N. W., Washington, DC,
 20005-3315, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2004132654	A1	20040708
APPLICATION INFORMATION:	US 2003-670563		20030926

	NUMBER	DATE
PRIORITY APPLN. INFO.:	DE 2002-102461252	20021001
FAMILY INFORMATION:	US 2004132654	20040708
DOCUMENT TYPE:	Utility	
	Patent Application - First Publication	
FILE SEGMENT:	CHEMICAL	
	APPLICATION	

NUMBER OF CLAIMS: 18

AB The invention relates to a concentrate and a process for producing a
factor VIII:C-containing von
Willebrand factor by fractional
precipitation from a liquid comprising **factor**
VIII:C and von Willebrand
factor, resulting in an increased content of high molecular
 weight multimers of **von Willebrand factor**
 and a ratio of the vWF:RCof activity to vWF:Ag of greater than 1.

CLMN 18

L7 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2004:172490 USPATFULL

TITLE: Concentrate of a **factor VIII**:
C-containing **von Willebrand**
factor and the process relating thereto

INVENTOR(S): Kumpé, Gerhardt, Wetter, GERMANY, FEDERAL REPUBLIC OF
Juraschek, Manfred, Weimar, GERMANY, FEDERAL REPUBLIC
OF
Mayer, Natascha, Marburg, GERMANY, FEDERAL REPUBLIC OF
Schulte, Stefan, Marburg, GERMANY, FEDERAL REPUBLIC OF
Wormshabacher, Wilfried, Kirchhain, GERMANY, FEDERAL
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004132654	A1	20040708
APPLICATION INFO.:	US 2003-670563	A1	20030926 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10246125	20021001
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	722	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a concentrate and a process for producing a
factor VIII:C-containing **von**
Willebrand factor by **fractional**
precipitation from a liquid comprising **factor**
VIII:C and **von Willebrand**
factor, resulting in an increased content of high molecular
weight multimers of **von Willebrand factor**
and a ratio of the vWF:RCof activity to vWF:Ag of greater than 1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 3 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 2004-297054 [28] WPIDS

DOC. NO. CPI: C2004-113576

TITLE: **Von Willebrand factor**
concentrates containing **Factor VIII**
C, having elevated high molecular multimer
content and low immunogenicity, useful for treating
hemophilia A and von Willebrand syndrome.

DERWENT CLASS: B04 D16

INVENTOR(S): JURASCHEK, M; KUMPE, G; MAYER, N; SCHULTE, S;
WORMSBAECHER, W; WORMSHABACHER, W

PATENT ASSIGNEE(S): (AVET) AVENTIS BEHRING GMBH; (CENT-N) CENTEON PHARMA
GMBH; (JURA-I) JURASCHEK M; (KUMP-I) KUMPE G; (MAYE-I)
MAYER N; (SCHU-I) SCHULTE S; (WORM-I) WORMSHABACHER W

COUNTRY COUNT: 35

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 1405863	A1	20040407 (200428)*	GE	14	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV					
MC MK NL PT RO SE SI SK TR					
CA 2443463	A1	20040401 (200428)	EN		
DE 10246125	A1	20040415 (200428)			
JP 2004123744	A	20040422 (200428)		16	
US 2004132654	A1	20040708 (200445)			
KR 2004030369	A	20040409 (200453)			

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 1405863	A1	EP 2003-20148	20030905
CA 2443463	A1	CA 2003-2443463	20030929
DE 10246125	A1	DE 2002-10246125	20021001
JP 2004123744	A	JP 2003-339076	20030930
US 2004132654	A1	US 2003-670563	20030926
KR 2004030369	A	KR 2003-68405	20031001

PRIORITY APPLN. INFO: DE 2002-10246125 20021001

AN 2004-297054 [28] WPIDS

AB EP 1405863 A UPAB: 20040429

NOVELTY - **Von Willebrand factor** (vWF)

concentrates (I) containing **Factor VIII:C**

(FVIII:C) are obtained by **fractional precipitation**

from a liquid containing FVIII:C and vWF; and have an elevated content of high molecular multimers of vWF and a ratio of vWF:RCoF (ristocetin cofactor) activity to vWF:Ag of more than 1, are new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for the preparation of (I).

ACTIVITY - Hemostatic.

MECHANISM OF ACTION - Blood coagulation factor.

USE - (I) are used in medicaments for treating hemophilia A and von Willebrand syndrome (claimed).

ADVANTAGE - The high content of high molecular multimers of vWF reduces the immunogenicity of recombinant or plasma FVIII:C (claimed), and thus reduces side-effects. Optimal vWF/FVIII:C with enriched high molecular multimer content are obtainable in simple and targeted manner by selective precipitation. The coagulation-active FVIII:C is stabilized by the vWF, and the high content of high molecular multimers provides a more rapid hemostatic action.

Dwg.0/0

=> d his

(FILE 'HOME' ENTERED AT 11:04:28 ON 02 AUG 2005)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, ...' ENTERED AT 11:05:21 ON 02 AUG 2005

L1 98 S FACTOR VIII:C AND WILLEBRAND FACTOR AND CONCENTRATE AND PREPA
L2 77 S L1 AND PY<2002
L3 72 DUP REM L2 (5 DUPLICATES REMOVED)
L4 0 S L3 AND ALKALI METAL AND (FRACTIONAL PRECIPITATION)
L5 0 S L3 AND FRACTIONAL PRECIPITATION
L6 4 S FRACTIONAL PRECIPITATION AND FACTOR VIII:C AND VON WILLEBRAND
L7 3 S L6 AND METAL

=>